

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2006 (28.12.2006)

PCT

(10) International Publication Number
WO 2006/137796 A1

(51) International Patent Classification:

C07D 205/08 (2006.01) A61P 3/06 (2006.01)
A61K 31/397 (2006.01) A61P 9/10 (2006.01)
A61P 25/28 (2006.01) C07D 405/12 (2006.01)

(21) International Application Number:

PCT/SE2006/000765

(22) International Filing Date: 21 June 2006 (21.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0501465-9 22 June 2005 (22.06.2005) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALENFALK, Susanne** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **DAHLSTRÖM, Mikael** [FI/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **HUNEGNAW, Fana** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **KARLSSON, Staffan** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **LEMURELL, Malin** [SE/SE]; AstraZeneca R &

D Mölndal, S-431 83 Mölndal (SE). **STARKE, Ingemar** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS



(I)

(57) Abstract: Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

WO 2006/137796 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

CHEMICAL COMPOUNDS

This invention relates to 2-azetidinone derivatives, or pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof. These 2-azetidinones possess cholesterol absorption inhibitory activity and are accordingly of value in the treatment of disease states associated with hyperlipidaemic conditions. They are therefore useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said 2-azetidinone derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit cholesterol absorption in a warm-blooded animal, such as man. A further aspect of this invention relates to the use of the compounds of the invention in the treatment of dyslipidemic conditions.

Atherosclerotic coronary artery disease is a major cause of death and morbidity in the western world as well as a significant drain on healthcare resources. It is well-known that hyperlipidaemic conditions associated with elevated concentrations of total cholesterol and low density lipoprotein (LDL) cholesterol are major risk factors for cardiovascular atherosclerotic disease (for instance "Coronary Heart Disease: Reducing the Risk; a Worldwide View" Assman G., Carmena R. Cullen P. *et al*; Circulation 1999, 100, 1930-1938 and "Diabetes and Cardiovascular Disease: A Statement for Healthcare Professionals from the American Heart Association" Grundy S, Benjamin I., Burke G., *et al*; Circulation, 1999, 100, 1134-46).

Sitosterolemia is a lipid storage disorder characterised by increased levels of sitosterol and other plant sterols in the plasma and other tissues due to increased non-selective intestinal absorption of sterols and decreased hepatic removal. Sitosterolemia can result in accelerated atherosclerosis and other cardiovascular diseases. See WO 02/058696.

The concentration of plasma cholesterol depends on the integrated balance of endogenous and exogenous pathways of cholesterol metabolism. In the endogenous pathway, cholesterol is synthesized by the liver and extra hepatic tissues and enters the circulation as lipoproteins or is secreted into bile. In the exogenous pathway cholesterol from dietary and biliary sources is absorbed in the intestine and enters the circulation as component of chylomicrons. Alteration of either pathway will affect the plasma concentration of cholesterol.

The precise mechanism by which cholesterol is absorbed from the intestine is however not clear.

A clear association between reduction of total cholesterol and (LDL) cholesterol and decreased instance of coronary artery disease has been established, and several classes of pharmaceutical agents are used to control serum cholesterol. The major options to regulate plasma cholesterol include (i) blocking the synthesis of cholesterol by agents such as HMG-CoA reductase inhibitors, for example statins such as simvastatin and fluvastatin, which also by up-regulation of LDL-receptors will promote the cholesterol removal from the plasma; (ii) blocking the bile acid reabsorption by specific agents resulting in increased bile acid excretion and synthesis of bile acids from cholesterol with agents such as bile acid binders, such as resins e.g. cholestyramine and cholestipol; and (iii) by blocking the intestinal uptake of cholesterol by selective cholesterol absorption inhibitors. High density lipoprotein (HDL) elevating agents such as fibrates and nicotinic acid analogues have also been employed.


Compounds possessing such cholesterol absorption inhibitory activity have been described, see for instance the compounds described in WO 93/02048, WO 94/17038, WO 95/08532, WO 95/26334, WO 95/35277, WO 96/16037, WO 96/19450, WO 97/16455, WO 02/50027, WO 02/50060, WO 02/50068, WO 02/50090, WO 02/66464, WO 04/000803, WO 04/000804, WO04/000805, WO04/01993, WO04/010948, WO04/043456 WO 04/043457, WO 04/081002, WO05/000353, WO05/021495, WO05/021497, WO05/033100, US 5756470, US 5767115, US 20040180860, US20040180861 and US RE37721.

The present invention is based on the discovery that certain 2-azetidinone derivatives surprisingly inhibit cholesterol absorption. Such properties are expected to be of value in the treatment of disease states associated with hyperlipidaemic conditions. The compounds of the present invention are not disclosed in any of the above applications and we have surprisingly found that the compounds of the present invention possess beneficial efficacious, metabolic and toxicological profiles that make them particularly suitable for *in vivo* administration to a warm blooded animal, such as man. In particular certain compounds of the present invention have a low degree of absorption compared to compounds of the prior art whilst retaining their ability to inhibit cholesterol absorption.

Accordingly there is provided a compound of formula (I):

A compound of formula (I):

- 3 -



5

Wherein:

\bar{X} = $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$;

10 R^1 = H, C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl;

R^2 and R^3 is hydrogen, a branched or unbranched C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl; wherein said C_{1-6} alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C_{1-6} alkoxy, $(\text{C}_1\text{-C}_4\text{ alkyl})_3\text{Si}$, N -(C_{1-6} alkyl)amino,

15 N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkylS(O) $_a$ wherein a is 0-2, C_{3-6} cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkoxy or ;

R^4 is hydrogen, C_{1-6} alkyl, or aryl C_{1-6} alkyl;

wherein R^3 and R^2 may form a ring with 3-7 carbon atoms and wherein R^4 and R^2 may form a


20 ring with 2-6 carbon atoms;

R^5 is selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl and

25 N,N -(C_{1-6} alkyl) $_2$ sulphamoyl; and wherein n is 0, 1, 2 or 3.

According to embodiments of the invention X can be $-\text{CH}_2-$, CH_2CH_2- , or $-\text{CH}_2\text{CH}_2\text{CH}_2-$.

Further the invention provides for a compound of formula (I2):



5

The substituents in the compound according to formula (I2) is the same as for the compound according to formula (I) as described above.

According to an embodiment of the invention R^1 is hydrogen;

- 10 R^2 and R^3 are hydrogen or a branched or unbranched C_{1-6} alkyl; wherein said C_{1-6} alkyl is substituted by C_{3-6} cycloalkyl, aryl or amino; and
 R^4 is hydrogen.

According to an embodiment of the invention R^1 is hydrogen;

- 15 R^2 and R^3 are hydrogen or a branched or unbranched C_{1-6} alkyl; wherein said C_{1-6} alkyl is substituted by C_{3-6} cycloalkyl;
 R^4 is hydrogen.

According to an embodiment of the invention, R^2 is hydrogen and R^3 is *tert*-butyl.

20

According to an embodiment of the invention, R^2 is hydrogen and R^3 is methyl; wherein said methyl is substituted by cyclohexyl .

According to an embodiment of the invention, R^5 is selected from chlorine or fluorine.

25

The invention further provides for a compound chosen from:

N-(4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-lysine;
N-(4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-*b,b*-dimethyl-D-phenylalanine; and
 5 *N*-(4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-Dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine ammoniate.

In this specification the term “alkyl” includes both straight and branched chain alkyl groups
 10 but references to individual alkyl groups such as “propyl” are specific for the straight chain version only. For example, “C₁₋₆alkyl” and “C₁₋₄alkyl” include propyl, isopropyl and *t*-butyl. However, references to individual alkyl groups such as ‘propyl’ are specific for the straight chained version only and references to individual branched chain alkyl groups such as ‘isopropyl’ are specific for the branched chain version only. A similar convention applies to
 15 other radicals, for example “phenylC₁₋₆alkyl” would include benzyl, 1-phenylethyl and 2-phenylethyl. The term “halo” refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from “one or more” groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

20 The term “aryl” refers to a 4-10 membered aromatic mono or bicyclic ring containing 0 to 5 heteroatoms independently selected from nitrogen, oxygen or sulphur. Examples of aryls include phenyl, pyrrolyl, furanyl, imidazolyl, triazolyl, tetrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridyl, isoxazolyl, oxazolyl, 1,2,4 oxadiazolyl, isothiazolyl, thiazolyl, 1,2,4-triazolyl, thienyl, naphthyl, benzofuranyl, benzimidazolyl, benzthienyl,
 25 benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, 1,3-benzodioxolyl, indolyl, pyridoimidazolyl, pyrimidoimidazolyl, quinolyl, isoquinolyl, quinoxalyl, quinazolinyl, phthalazinyl, cinnolinyl and naphthyridinyl. Particularly “aryl” refers to phenyl, thienyl, pyridyl, imidazolyl or indolyl. The term “aryl” includes both unsubstituted and substituted aromatic rings.

30 Examples of “C₁₋₆alkoxy” include methoxy, ethoxy and propoxy. Examples of “C₁₋₆alkylS(O)_a wherein a is 0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of “*N*-(C₁₋₆alkyl)amino” include methylamino and ethylamino. Examples of “*N,N*-(C₁₋₆alkyl)₂amino” include

carbonate esters), dialkylcarbamoyl and *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

- 5 A suitable value for an *in vivo* hydrolysable amide of a compound of the formula (I), or other compounds disclosed herein, containing a carboxy group is, for example, a *N*-C₁₋₆alkyl or *N,N*-di-C₁₋₆alkyl amide such as *N*-methyl, *N*-ethyl, *N*-propyl, *N,N*-dimethyl, *N*-ethyl-*N*-methyl or *N,N*-diethyl amide.

- Some compounds of the formula (I) may have chiral centres and/or geometric
10 isomeric centres (*E*- and *Z*- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess cholesterol absorption inhibitory activity.


 The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess cholesterol absorption inhibitory activity.

- 15 It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms, which possess cholesterol absorption inhibitory activity.

- 20 Preferred aspects of the invention are those, which relate to the compound of formula (I) or a pharmaceutically acceptable salt thereof.

- Another aspect of the present invention provides a process for preparing a compound
25 of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:

Process 1) reacting a compound of formula (II):



di-*N*-methyamino, di-(*N*-ethyl)amino and *N*-ethyl-*N*-methyamino. "C₃₋₆cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

A suitable pharmaceutically acceptable salt of a compound of the invention, or other compounds disclosed herein, is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric, acetate or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

The compounds of the formula (I), or other compounds disclosed herein, may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I). Examples of pro-drugs include *in vivo* hydrolysable esters and *in vivo* hydrolysable amides of a compound of the formula (I).


An *in vivo* hydrolysable ester of a compound of the formula (I), or other compounds disclosed herein, containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

An *in vivo* hydrolysable ester of a compound of the formula (I), or other compounds disclosed herein, containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl

- 8 -

(II)


with a compound of formula (III):



(III)


5 wherein L is a displaceable group;

Process 2) reacting an acid of formula (IV):




(IV)

or an activated derivative thereof; with an amine of formula (V):



(V)


Process 3): reacting an acid of formula (VI):



(VI)


15 or an activated derivative thereof, with an amine of formula (VII):

- 9 -




(VII)

Process 4): reducing a compound of formula (VIII):




(VIII)

Process 5): reacting a compound of formula (IX):



(IX)

with a compound of formula (X):




(X)

wherein L is a displaceable group;


Process 6): reacting a compound of formula (XI):

- 10 -




(XI)

5 wherein L is a displaceable group; with a compound of formula (XII):



(XII)

Process 7): De-esterifying a compound of formula (XIII)



(XIII)

wherein the group C(O)OR is an ester group;

and thereafter if necessary or desirable:

- 15 i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug; or
- iv) separating two or more enantiomers.


L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.

C(O)OR is an ester group, suitable values for C(O)OR are methoxycarbonyl, 5 ethoxycarbonyl, *t*-butoxycarbonyl and benzyloxycarbonyl.

The starting materials used in the present invention can be prepared by modifications of the routes described in EP 0 792 264 B1. Alternatively they can be prepared by the following reactions.

Process 1): Alcohols of formula (II) may be reacted with compounds of formula (III) in the 10 presence of a base for example an inorganic base such as sodium carbonate, or an organic base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile, dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably at or near reflux.

Compounds of formula (II) may be prepared according to the following scheme:




Scheme 1

wherein pMeOBz is para methoxy benzyl.

Compounds of formula (IIb), (IIId), (IIg) and (III) are commercially available
 5 compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Another aspect of the present invention provides a process for preparing a compound of formula (I2)




5

(I2)

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:


Process 1) reacting a compound of formula (II2):



10

(II2)

with a compound of formula (III):




(III)

15 wherein L is a displaceable group;


Process 2) reacting an acid of formula (IV2):

- 14 -




(IV2)

or an activated derivative thereof; with an amine of formula (V):




(V)

Process 3): reacting an acid of formula (VI2):




(VI2)

or an activated derivative thereof, with an amine of formula (VII):




(VII)

Process 4): reducing a compound of formula (VIII2):




(VIII2)

Process 5): reacting a compound of formula (IX2):



(IX2)


with a compound of formula (X):



(X)

wherein L is a displaceable group;


10 Process 6): reacting a compound of formula (XI2):



(XI2)


wherein L is a displaceable group; with a compound of formula (XII):

- 16 -



(XII)

Process 7): De-esterifying a compound of formula (XIII2)



(XIII2)

5

wherein the group C(O)OR is an ester group;

and thereafter if necessary or desirable:

- i) converting a compound of the formula (I2) into another compound of the formula (I2);
- 10 ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug; or
- iv) separating two or more enantiomers.

L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or

- 15 toluene-4-sulphonyloxy group.


C(O)OR is an ester group, suitable values for C(O)OR are methoxycarbonyl, ethoxycarbonyl, *t*-butoxycarbonyl and benzyloxycarbonyl.

- The starting materials used in the present invention can be prepared by modifications of the routes described in EP 0 792 264 B1. Alternatively they can be prepared by the
- 20 following reactions.

Process 1): Alcohols of formula (II2) may be reacted with compounds of formula (III) in the presence of a base for example an inorganic base such as sodium carbonate, or an organic base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile, dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably

- 25 at or near reflux.

Compounds of formula (II2) may be prepared according to the following scheme:




Scheme 1

wherein pMeOBz is para methoxy benzyl.


- 5 Compounds of formula (IIb), (IIId), (IIg2) and (III2) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

A compound of formula (V) may also be reacted with a compound of formula (XIV).

- 19 -




Compounds of formula XIV may be prepared by the following route:




A compound of formula (III2) may also be reacted with a compound of formula (XIV2).

5

Compounds of formula (XIV2) may be prepared according to the following route:




A compound of formula (XV) may be reduced to a compound of formula (IV) or a compound of formula (XV) may be reacted with a compound of formula (V):



(XV)

A compound of formula (XV2) may be reduced to a compound of formula (IV2) or a compound of formula (XV2) may be reacted with a compound of formula (V)




(XV2)

5


Compounds of formula (XV2) may be prepared according to the following route:

10



The steps in this scheme are not restricted to the reagents, conditions or protecting groups mentioned.

Compounds of formula (XV2) may be prepared according to the following scheme:



The steps in this scheme are not restricted to the reagents, conditions or protecting groups mentioned.

For XIV and (XV), and in an analogous manner for XIV2 and (XV2) both the following applies:

Process 2) and *Process 3)*: Acids and amines may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, for example carbonyldiimidazole and
5 dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-*alkyl*-pyridines such as 2,6-lutidine or 2,6-di-*tert*-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be
10 performed at a temperature in the range of -40 to 40°C.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those
15 described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

Acids of formula (IV) and (VI) may be prepared from compounds of formula (II) by reacting them with the appropriate, optionally protected, side chain using the conditions of *Process 1)*. Alternatively, acids of formula (IV) and (VI) may be prepared by a modification
20 of *Scheme I*.

Amines of formula (V) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Process 4): Reduction of compounds of formula (VIII) could be performed with a hydride reagent such as sodium borohydride in a solvent such as methanol at temperatures suitable
25 between -20-40°C.

Compounds of formula (VIII) can be prepared from compounds of formula (III), by deprotecting the benzyl group and performing *Process 1*. Alternatively compound (IIIk) could be debenzylated, *Process 1* could be performed and the resulting compound deprotected to reveal the ketone.
30 *Process 5)* and *Process 6)*: these compounds may be reacted together in the presence of a base for example an inorganic base such as sodium carbonate, or an organic base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile, dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably at or near reflux.

Compounds of formula (IX) and (XI) may be prepared by an appropriate modification of *Scheme 1*.

Compounds of formula (X) and (XII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

5 *Process 7*): Esters of formula (XIII) may be deprotected under standard conditions such as those described below, for example a methyl or ethyl ester may be deprotected with sodium hydroxide in methanol at room temperature.

Compounds of formula (XIII) may be prepared by a modification of any of the processes described herein for the preparation of compounds of formula (I).

10 It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a
15 substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as
20 aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic
hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric
25 acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard
30 practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1999). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.


A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

The invention further provides for a compound of the formula (XVI) or hydrolysable esters or amides thereof:




(XVI)

5

wherein R⁷ is an hydroxy group or a C₁₋₄ alkoxy group. R¹, is as defined above regarding formula (I). A compound of formula (XVI) may be an intermediate to formula (I).

The invention further provides for a compound of the formula (XVI2) or hydrolysable esters
10 or amides thereof:



(XVI2)

15 wherein R⁷ is an hydroxy group or a C₁₋₃ alkoxy group. R¹ is as defined above regarding formula (I). A compound of formula (XVI2) may be an intermediate to formula (I2).

As stated hereinbefore the compounds defined in the present invention possess cholesterol absorption inhibitory activity. These properties may be assessed, using the following biological tests.

20

In vivo testing of cholesterol absorption inhibitors (A)

C57BL/6 female mice were maintained on regular chow diet and housed in individual cages to collect faeces. Mice were fasted for 3 hours and then gavaged with vehicle or compound. Half an hour later the mice were gavaged with radiolabelled cholesterol. Six hours after the ¹⁴C-cholesterol gavage blood samples were taken via the tail and plasma prepared to determine how much cholesterol were absorbed. 24 hours after the gavage of ¹⁴C-cholesterol the mice were bled and plasma were prepared for analysis. Faeces were collected for 24 hours to assess absorption efficiency.

In vivo testing of cholesterol absorption inhibitors (B).

C57BL/6 female mice were maintained on regular chow diet and housed in individual cages to collect faeces. Mice were fasted for 3 hours and then gavaged with vehicle or compound. One to ten hours later the mice were gavaged with radiolabelled cholesterol. Six hours after the ¹⁴C-cholesterol gavage blood sample was taken via the tail and plasma prepared to determine how much cholesterol was absorbed. 24 hours after the gavage of ¹⁴C-cholesterol the mice were bled and plasma analysed for radioactivity. Faeces were also collected for 24 hours to assess absorption efficiency.

References

1. E. A. Kirk, G. L. Moe, M. T. Caldwell, J. Å. Lernmark, D. L. Wilson, R. C. LeBoeuf. Hyper- and hypo-responsiveness to dietary fat and cholesterol among inbred mice: searching for level and variability genes. J. Lipid Res. 1995 36:1522-1532.
 2. C. P. Carter, P. N. Howles, D. Y. Hui. Genetic variation in cholesterol absorption efficiency among inbred strains of mice. J. Nutr. 1997 127:1344-1348.
 3. C. D. Jolley, J. M. Dietschy, S. D. Turley. Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Am. J. Physiol. 1999 276:G1117-G1124.
- Administration of 0.2 µmol/kg of Example 3 gave 59% inhibition of ¹⁴C-cholesterol absorption (procedure A). Administration of 0.2 µmol/kg of Example 4 gave 53 % inhibition of ¹⁴C-cholesterol absorption (procedure A).

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

5 In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, will normally be administered to a warm-blooded animal at a unit dose within the range of approximately 0.02-100 mg/kg, preferably 0.02 -50 mg/kg,
10 and this normally provides a therapeutically-effective dose. Preferably a daily dose in the range of 1-50 mg/kg, particularly 0.1-10 mg/kg is employed. In another aspect a daily dose in the range of 0.01-20 mg/kg is employed. In one aspect of the invention the daily dose of a compound of formula (I) is less than or equal to 100 mg. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration,
15 and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.

According to a further aspect of the present invention there is provided a compound of
20 the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are
25 effective cholesterol absorption inhibitors, and accordingly have value in the treatment of disease states associated with hyperlipidaemic conditions.

Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use as a medicament.

30 According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the

production of a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
5 prodrug thereof, as defined hereinbefore in the production of a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man.

Herein, where the production of a cholesterol absorption inhibitory effect or a cholesterol lowering effect is stated, suitably this relates to the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man. Additionally it relates to the treatment of
10 dyslipidemic conditions and disorders such as hyperlipidaemia, hypertriglyceridemia, hyperbetalipoproteinemia (high LDL), hyperprebetalipoproteinemia (high VLDL), hyperchylomicronemia, hypolipoproteinemia, hypercholesterolemia, hyperlipoproteinemia and hypoalphalipoproteinemia (low HDL) in a warm-blooded animal, such as man. Furthermore it relates to the treatment of different clinical conditions such as atherosclerosis,
15 arteriosclerosis, arrhythmia, hyper-thrombotic conditions, vascular dysfunction, endothelial dysfunction, heart failure, coronary heart diseases, cardiovascular diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, inflammation of cardiovascular tissues such as heart, valves, vasculature, arteries and veins, aneurisms, stenosis, restenosis, vascular plaques, vascular fatty streaks, leukocytes, monocytes and/or macrophage
20 infiltration, intimal thickening, medial thinning, infectious and surgical trauma and vascular thrombosis, stroke and transient ischaemic attacks in a warm-blooded animal, such as man. It also relates to the treatment of atherosclerosis, coronary heart diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, stroke and transient ischaemic attacks in a warm-blooded animal, such as man.

25 The production of a cholesterol absorption inhibitory effect or a cholesterol lowering effect also relates to a method of treating and/or preventing atherosclerotic lesions, a method of preventing plaque rupture and a method of promoting lesion regression. Furthermore it relates to a method of inhibiting monocytes-macrophage accumulation in atherosclerotic lesions, a method of inhibiting expression of matrix metalloproteinases in atherosclerotic
30 lesions, a method of inhibiting the destabilization of atherosclerotic lesions, a method for preventing atherosclerotic plaque rupture and a method of treating unstable angina.

The production of a cholesterol absorption inhibitory effect or a cholesterol lowering effect also relates to a method of treating sitosterolemia.

Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may also have value in the treatment or prevention of Alzheimer's Disease (see for example WO 02/096415). Therefore in a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in the treatment or prevention of Alzheimer's Disease.

Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may also have value in the treatment or prevention cholesterol associated tumors. Therefore in a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in the treatment or prevention of cholesterol associated tumors.

Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may also have value in the treatment or prevention of vascular inflammation (see for example WO 03/026644). Therefore in a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in the treatment or prevention of vascular inflammation.

According to a further feature of this aspect of the invention there is provided a method for producing a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

The cholesterol absorption inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore and an additional cholesterol absorption inhibitory substance as defined hereinbefore and an additional hypolipidaemic agent for the conjoint treatment of hyperlipidaemia.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with cholesterol biosynthesis inhibitors, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable cholesterol biosynthesis inhibitors include HMG Co-A reductase inhibitors, squalene synthesis inhibitors and squalene epoxidase inhibitors. Suitable squalene synthesis inhibitors are e.g. squalastatin 1, TAK 475 and compounds described in WO2005012284. A suitable squalene epoxidase inhibitor is NB-598.

In this aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with an HMG Co-A reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable HMG Co-A reductase inhibitors, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are statins well known in the art. Particular statins are fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, dalvastatin, mevastatin and rosuvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A further particular statin is pitavastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A further particular statin is rosuvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A preferable particular statin is rosuvastatin calcium salt.

Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

10 According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- 15 c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- 20 b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

25 According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect.

30 According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the

simultaneous, sequential or separate administration of an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

5 According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of a matrix metalloproteinase
10 inhibitor.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with an ileal bile acid (IBAT) inhibitor or a pharmaceutically acceptable salt,
15 solvate, solvate of such a salt or a prodrug thereof. Suitable compounds possessing IBAT inhibitory activity for use in combination with compounds of the present invention have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO 94/24087, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/07749, WO 98/38182, WO 98/40375, WO 98/56757, WO 99/32478, WO 99/35135, WO
20 99/64409, WO 99/64410, WO 00/01687, WO 00/20392, WO 00/20393, WO 00/20410, WO 00/20437, WO 00/35889, WO 01/34570, WO 00/38725, WO 00/38726, WO 00/38727, WO 00/38728, WO 00/38729, WO 00/47568, WO 00/61568, WO 01/66533, WO 01/68096, WO 01/68637, WO 02/08211, WO 02/50051, WO 03/018024, WO 03/040127, WO 03/043992, WO 03/061604, WO 04/020421, WO 04/076430, DE 19825804, JP 10072371, US 5070103,
25 EP 251 315, EP 417 725, EP 489 423, EP 549 967, EP 573 848, EP 624 593, EP 624 594, EP 624 595, EP 864 582, EP 869 121 and EP 1 070 703, WO 03/020710, WO 03/022825, WO 03/022830, WO 03/022286, WO 03/091232, WO 03/106482, and EP 597 107
and the contents of these patent applications are incorporated herein by reference. Particularly the named examples of these patent applications are incorporated herein by reference. More
30 particularly claim 1 of these patent application are incorporated herein by reference.


Other suitable classes of IBAT inhibitors for use in combination with compounds of the present invention are the benzothiepinines, 1,2-benzothiazepines, 1,4-benzothiazepines and

1,5-benzothiazepines. A further suitable class of IBAT inhibitors is the 1,2,5-benzothiadiazepines.

One particular suitable compound possessing IBAT inhibitory activity for use in combination with compounds of the present invention is (3*R*,5*R*)-3-butyl-3-ethyl-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl beta-D-glucopyranosiduronic acid (EP 864 582).

A further suitable compound possessing IBAT inhibitory activity for use in combination with compounds of the present invention is S-8921 (EP 597 107) and BARI-1741.

10 A further suitable IBAT inhibitor for use in combination with compounds of the present invention is the compound:



WO 99/32478

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-120 of WO 02/50051, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-120 are incorporated herein by reference. Claims 1-15 of WO 02/50051 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 02/50051 for use in combination with compounds of the present invention is selected from any one of:

15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-(*R*)-1'-phenyl-1'-[*N'*-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-(*R*)- α -[*N'*-(carboxymethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 5 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(5-carboxypentyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{ α -[*N'*-(2-sulphoethyl)carbamoyl]-2-fluorobenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{(R)-1-[*N''*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]-2-hydroxyethyl}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 25 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{ α -[*N'*-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{ α -[*N'*-((ethoxy)(methyl)phosphorylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 30 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{2-[(hydroxy)(methyl)phosphoryl]ethyl}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-methylthio-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{2-[(methyl)(ethyl)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{2-[(methyl)(hydroxy)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[(R)-*N'*-(2-methylsulphinyl)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; and

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8-[*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-44 of WO 03/020710, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-44 are incorporated herein by reference. Claims 1-10 of WO 03/020710 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/020710

for use in combination with compounds of the present invention is selected from any one of:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carbamoyl-2-hydroxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(hydroxycarbamoyl-methyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[*N*-((R)- α -{*N'*-[2-(*N'*-pyrimidin-2-ylureido)ethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- α -{N'-[2-(N'-pyridin-2-ylureido)ethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(1-t-butoxycarbonylpiperidin-4-ylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2,3-dihydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 10 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- α -{N'-[2-(3,4-dihydroxyphenyl)-2-methoxyethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-aminoethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 15 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(piperidin-4-ylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; or
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-N,N-dimethylaminosulphamoyl)ethyl]carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 20 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-7 of WO 03/022825, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-7 are incorporated herein by reference. Claims 1-8 of WO 03/022825 are also

25 incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/022825 for use in combination with compounds of the present invention is selected from any one of:

1,1-dioxo-3(R)-3-butyl-3-ethyl-5-(R)-5-phenyl-8-[N-((R)- α -carboxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,4-benzothiazepine;

1,1-dioxo-3(S)-3-butyl-3-ethyl-5-(S)-5-phenyl-8-[N-((R)- α -carboxybenzyl)

30 carbamoylmethoxy]-2,3,4,5-tetrahydro-1,4-benzothiazepine;

1,1-dioxo-3(R)-3-butyl-3-ethyl-5-(R)-5-phenyl-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

1,1-dioxo-3(S)-3-butyl-3-ethyl-5-(S)-5-phenyl-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

3,5-*trans*-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-bromo-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-

5 benzothiazepine;

3,5-*trans*-1,1-dioxo-3-(S)-3-ethyl-3-butyl-4-hydroxy-5-(S)-5-phenyl-7-bromo-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine

3,5-*trans*-1,1-dioxo-3-(R)-3-ethyl-3-butyl-4-hydroxy-5-(R)-5-phenyl-7-bromo-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-

10 benzothiazepine;

3,5-*trans*-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

15 3,5-*trans*-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine ammonia salt;

1,1-dioxo-3-(S)-3-ethyl-3-butyl-5-(S)-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-

20 benzothiazepine diethylamine salt; and

1,1-dioxo-3-(R)-3-ethyl-3-butyl-5-(R)-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine diethylamine salt;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

25 A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-4 of WO 03/022830, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-4 are incorporated herein by reference. Claims 1-8 of WO 03/022830 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/022830

30 for use in combination with compounds of the present invention is selected from any one of: 1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine

1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(*N*-{(R)- α -[*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine ammonia salt

1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-{*N*-[α -(carboxy)-2-fluorobenzyl]carbamoylmethylthio}-2,3,4,5-tetrahydrobenzothiepine; and

5 1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-{*N*-[1-(carboxy)-1-(thien-2-yl)methyl]carbamoylmethylthio}-2,3,4,5-tetrahydrobenzothiepine

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-39 of WO 03/022286, or a pharmaceutically

10 acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-39 are incorporated herein by reference. Claims 1-10 of WO 03/022286 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/022286 for use in combination with compounds of the present invention is selected from any one of: 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-

25 benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-{(S)-1-[*N*-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((R)- α -carboxy-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

- A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-7 of WO 03/091232, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-7 are incorporated herein by reference. Claims 1-10 of WO 03/091232 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/091232 for use in combination with compounds of the present invention is selected from any one of:
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((*R/S*)- α -{*N*-[1-(*R*)-2-(*S*)-1-hydroxy-1-(3,4-dihydroxyphenyl)prop-2-yl]carbamoyl}-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(*R*)- α -(*N*-{2-(*S*)-[*N*-(carbamoylmethyl)carbamoyl]pyrrolidin-1-ylcarbonylmethyl}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((*R*)- α -{*N*-[2-(3,4,5-trihydroxyphenyl)ethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

10 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N*-(2-(*R*)-3-(*S*)-4-(*S*)-5-(*R*)-3,4,5,6-tetrahydroxytetrahydropyran-2-ylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Further suitable compounds possessing IBAT inhibitory for use in combination with

15 compounds of the present invention are disclosed in WO 03/106482

Suitable IBAT inhibitors having the above structure for use in combination with compounds of the present invention are selected from any one of:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxybutyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylbutyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylbutyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-

- mesylethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylsulphonylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 5 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-mesylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylbutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylbutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-hydroxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylthioethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylsulphinylethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-mesyloethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methoxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylthiopropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylsulphonylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-mesylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-

15 benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; or

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine.

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Further suitable IBAT inhibitors for use in combination with compounds of the present invention are those disclosed in WO 04/076430.

In a particular aspect of the invention an IBAT inhibitor or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof is an IBAT inhibitor or a pharmaceutically acceptable salt thereof.

Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a

compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

5 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

10 According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

 According to a further aspect of the present invention there is provided a kit

15 comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- b) an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and

20 c) container means for containing said first and second dosage forms.

 According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a
- 25 first unit dosage form;
- b) an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

 According to another feature of the invention there is provided the use of a compound

30 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the

5 simultaneous, sequential or separate administration of an effective amount of an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

10 According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of an IBAT
15 inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in
20 association with a PPAR alpha and/or gamma and/or delta agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma and/or delta agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO
25 98/57941, WO 01/40170, WO 01/40172, WO 02/085844, WO 02/096863, WO03/051821, WO03/051822, WO03/051826, WO 04/000790, WO04/000295, WO04/000294, PCT/GB03/02584, PCT/GB03/02591, PCT/GB03/02598, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all
30 incorporated herein by reference. Particularly a PPAR alpha and/or gamma and/or delta agonist refers to muraglitazar (BMS 298585), rivoglitazone (CS-011), netoglitazone (MCC-555), balaglitazone (DRF-2593, NN-2344), clofibrate, fenofibrate, bezafibrate, gemfibrozil, ciprofibrate, beclofibrate, etofibrate, gemcabene, pioglitazone, rosiglitazone, edaglitazone,

LY-293111, MBX-2044, AVE-0847, AVE-8134, CLX-0921, DRF-10945, DRF-4832, LY-518674, naveglitazar (LY-818), LY-929, 641597, GW-590735, GW-677954, GW-501516, metaglidazen (MBX-102), T-131, SDX-101 E-3030, PLX-204, ONO-5129, KRP-101, R-483 (BM131258), TAK-559, K-111 (BM170744), netoglitazone (MCC-555; RWJ-241947; 5 isaglitazone), FK-614 or TAK-654

Particularly a PPAR alpha and/or gamma and/or delta agonist refers to (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy) phenyl]propanoic acid (tesaglitazar) and 10 pharmaceutically acceptable salts thereof.

Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

15 Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective 20 amount of a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma 25 and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma and/or delta agonist, or a 30 pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- b) a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- 5 c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a
- 10 first unit dosage form;
- b) a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound

15 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in producing a cholesterol lowering effect in a warm-blooded animal, such as man.

20 According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of a PPAR alpha

25 and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

30 In another aspect of the invention, there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the

simultaneous, sequential or separate administration of an -agonists to the receptor HM74A (nicotinic acid receptor). HM74A receptor agonists may be nicotine acid derivatives. As used herein "nicotinic acid derivative" means a compounds comprising a pyridine-3-carboxylate structure or a pyrazine-2-carboxylate structure. Examples of nicotinic acid derivatives include
5 nicotinic acid, niceritrol, nicofuranose, NIASPAN® and acipimox.

HM74A receptor agonists may be anthranilic acid derivatives described in WO-2005016867 and WO-2005016870.

10 Other nicotinic receptor agonists are for example compounds described in WO2005011677, WO2004032928 and WO2004033431.

Therefore, in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a
15 salt or a prodrug thereof and a HM74A receptor agonists or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a
20 compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a HM74A receptor agonists, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical
25 composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a HM74A receptor agonists, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

30 In another aspect of the invention, there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the

simultaneous, sequential or separate administration of a mediator of reverse cholesterol transport i.e. a peptide (Apo A-1 mimetic peptides) or small molecule mediator of reverse cholesterol transport e.g. those described in Circ. 2002;105:290, Circ. 2004.109:3215, Curr.Opinion in Lipidology 2004,15:645 or in WO2004094471.

5

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with an anti-obesity compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example a pancreatic lipase inhibitor e.g. orlistat
10 (EP 129,748) or an appetite (satiety) controlling substance for example sibutramine (GB 2,184,122 and US 4,929,629), a cannabinoid 1 (CB1) antagonist or inverse agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example rimonabant (EP 656354) and as described in WO01/70700 or a melanin concentrating hormone (MCH) antagonist, or pharmaceutically acceptable salts, solvates,
15 solvates of such salts or prodrugs thereof, for example as described in WO 04/004726.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
20 prodrug thereof, and a nicotinic acid derivative, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in
25 association with a bile acid sequestrant or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. Suitable bile acid sequestrants include cholestyramine, cholestipol and cosevelam hydrochloride.

Therefore, in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a
30 salt or a prodrug thereof and a bile acid sequestrant or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of

such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a bile acid sequestrant, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid sequestrant, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid sequestrant, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a cholesteryl ester transfer protein (CETP) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example JTT-705, torcetrapib (CP-529414), Bay 194789 and those referenced and described in WO05033082 or WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference.

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a acyl coenzymA: cholesterol O-acyltransferase (ACAT) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example pactimibe (CS-505), eflucimibe (F-12511) and SMP-797, avasimibe or K604.

In yet another aspect of the invention, the compound of formula I, association with modulators for example GW-4064 and INT-747 of nuclear receptors such as farnesoid or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be

administered in X receptor (FXR), or pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a phytosterol compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example stanols. An example of phytosterol analogs is FM-VP4.

10 In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with other therapies for the treatment of metabolic syndrome or type 2 diabetes and its associated complications, these include biguanide drugs, for example metformin, phenformin and buformin, insulin (synthetic insulin analogues, amylin) and oral
15 antihyperglycemics (these are divided into prandial glucose regulators and alpha-glucosidase inhibitors). An example of an alpha-glucosidase inhibitor is acarbose or voglibose or miglitol. An example of a prandial glucose regulator is repaglinide or nateglinide.

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in
20 association with a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, gliquidone, chlorpropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolcyclamide and tolazamide. Preferably the sulfonylurea is glimepiride or glibenclamide (glyburide). More preferably the sulfonylurea is
25 glimepiride. Therefore the present invention includes administration of a compound of the present invention in conjunction with one, two or more existing therapies described in this paragraph. The doses of the other existing therapies for the treatment of type 2 diabetes and its associated complications will be those known in the art and approved for use by regulatory bodies for example the FDA and may be found in the Orange Book published by the FDA.
30 Alternatively smaller doses may be used as a result of the benefits derived from the combination.

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier,
5 with the simultaneous, sequential or separate administration one or more of the following agents selected from Group X:

- an antihypertensive compound (for example althiazide, benzthiazide, captopril, carvedilol, chlorothiazide sodium, clonidine hydrochloride, cyclothiazide, delapril hydrochloride, dilevalol hydrochloride, doxazosin mesylate, fosinopril sodium, 10 guanfacine hydrochloride, methyldopa, metoprolol succinate, moexipril hydrochloride, monatepil maleate, pelanserine hydrochloride, phenoxybenzamine hydrochloride, prazosin hydrochloride, primidolol, quinapril hydrochloride, quinaprilat, ramipril, terazosin hydrochloride, candesartan, candesartan cilexetil, telmisartan, amlodipine besylate, amlodipine maleate and bevantolol hydrochloride);
- 15 ➤ an angiotensin converting enzyme inhibitor (for example alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, 20 hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanapril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, 25 zofenopril and zofenoprilat);
- an angiotensin II receptor antagonist (for example candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan);
- 30 ➤ an adrenergic blocker (for example bretylium tosylate, dihydroergotamine so mesylate, phentolamine mesylate, solypertine tartrate, zolertine hydrochloride, carvedilol or labetalol hydrochloride); an alpha adrenergic blocker (for example fenspiride hydrochloride, labetalol hydrochloride, proroxan and alfuzosin

- hydrochloride); a beta andrenergic blocker (for example acebutolol, acebutolol hydrochloride, alprenolol hydrochloride, atenolol, bunolol hydrochloride, carteolol hydrochloride, celiprolol hydrochloride, cetamolol hydrochloride, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacetolol hydrochloride, dilevalol hydrochloride, esmolol hydrochloride, exaprolol hydrochloride, fleistolol sulfate, labetalol hydrochloride, levobetaxolol hydrochloride, levobunolol hydrochloride, metalol hydrochloride, metoprolol, metoprolol tartrate, nadolol, pamatolol sulfate, penbutolol sulfate, practolol, propranolol hydrochloride, sotalol hydrochloride, timolol, timolol maleate, tiprenolol hydrochloride, tolamolol, bisoprolol, bisoprolol fumarate and nebivolol); or a mixed alpha/beta andrenergic blocker;
- an andrenergic stimulant (for example combination product of chlorothiazide and methyldopa, the combination product of methyldopa hydrochlorothiazide and methyldopa, clonidine hydrochloride, clonidine, the combination product of chlorthalidone and clonidine hydrochloride and guanfacine hydrochloride);
- channel blocker, for example a calcium channel blocker (for example clentiazem maleate, amlodipine besylate, isradipine, nimodipine, felodipine, nilvadipine, nifedipine, teludipine hydrochloride, diltiazem hydrochloride, belfosdil, verapamil hydrochloride or fostedil);
- a diuretic (for example the combination product of hydrochlorothiazide and spironolactone and the combination product of hydrochlorothiazide and triamterene);
- anti-anginal agents (for example amlodipine besylate, amlodipine maleate, betaxolol hydrochloride, bevantolol hydrochloride, butoprozine hydrochloride, carvedilol, cinepazet maleate, metoprolol succinate, molsidomine, monatepil maleate, primidolol, ranolazine hydrochoride, tosifen or verapamil hydrochloride);
- vasodilators for example coronary vasodilators (for example fostedil, azaclozine hydrochloride, chromonar hydrochloride, clonitrate, diltiazem hydrochloride, dipyridamole, droprenilamine, erythrityl tetranitrate, isosorbide dinitrate, isosorbide mononitrate, lidoflazine, mioflazine hydrochloride, mixidine, molsidomine, nicorandil, nifedipine, nisoldipine, nitroglycerine, oxprenolol hydrochloride, pentrinitrol, perhexiline maleate, prenylamine, propatyl nitrate, terodiline hydrochloride, tolamolol and verapamil);

- anti-coagulants (selected from argatroban, bivalirudin, dalteparin sodium, desirudin, dicumarol, Iyapolate sodium, nafamostat mesylate, phenprocoumon, tinzaparin sodium and warfarin sodium);
- antithrombotic agents (for example anagrelide hydrochloride, bivalirudin, cilostazol, dalteparin sodium, danaparoid sodium, dazoxiben hydrochloride, efegatran sulfate, enoxaparin sodium, fluretofen, ifetroban, ifetroban sodium, lamifiban, lotrafiban hydrochloride, napsagatran, orbofiban acetate, roxifiban acetate, sibrafiban, tinzaparin sodium, trifenagrel, abciximab and zolimomab aritox);
- fibrinogen receptor antagonists (for example roxifiban acetate, fradafiban, orbofiban, lotrafiban hydrochloride, tirofiban, xemilofiban, monoclonal antibody 7E3 and sibrafiban)
- platelet inhibitors (for example cilostezol, clopidogrel bisulfate, epoprostenol, epoprostenol sodium, ticlopidine hydrochloride, aspirin, ibuprofen, naproxen, sulindae, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone and piroxicam, dipyridamole);
- platelet aggregation inhibitors (for example acadesine, beraprost, beraprost sodium, ciprostone calcium, itezigrel, lifarizine, lotrafiban hydrochloride, orbofiban acetate, oxagrelate, fradafiban, orbofiban, tirofiban and xemilofiban)
- hemorrhheologic agents (for example pentoxifylline);
- lipoprotein associated coagulation inhibitors;
- Factor VIIa inhibitors;
- Factor Xa inhibitors;
- low molecular weight heparins (for example enoxaparin, nardropan, dalteparin, certropan, parnaparin, reviparin and tinzaparin);
- squalene synthase inhibitors;
- liver X receptor (LXR) agonists for example GW-3965 and those described in WO00224632, WO00103705, WO02090375 and WO00054759 (claim 1 and the named examples of these four application are incorporated herein by reference);
- microsomal triglyceride transfer protein inhibitors for example implitapide ,CP-346086, JTT-130, BMS-201038, R-103757 and those described in WO05/021486, WO03004020, WO03002533, WO02083658 and WO 00242291

(claim 1 and the named examples of these four application are incorporated herein by reference);

- ApoA1 expression inducer for example those described in WO2005032559 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Therefore, in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a compound from Group X or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

In addition to their use in therapeutic medicine, the compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cholesterol absorption in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

What has been described above regarding the combination therapy with a compound of formula (I), and the use of a compound of formula (I) for the treatment or prophylaxis of various diseases and conditions also apply for compound (I2).

Many of the intermediates described herein are novel and are thus provided as a further feature of the invention. For example compounds of formula (XVI) show cholesterol absorption inhibitory activity when tested in the above referenced *in vitro* test assay and are thus claimed as a further feature of the invention.

Thus in a further feature of the invention, there is provided a compound of formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore according to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in association with a pharmaceutically-acceptable diluent or carrier.

According to an additional aspect of the present invention there is provided a compound of the formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

Thus according to this aspect of the invention there is provided a compound of the formula (VI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use as a medicament.

According to another feature of the invention there is provided the use of a compound of the formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (XVI) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further feature of this aspect of the invention there is provided a method for producing a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further feature of this aspect of the invention there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

15 Examples

The invention will now be illustrated in the following non limiting Examples, in which standard techniques known to the skilled chemist and techniques analogous to those described in these Examples may be used where appropriate, and in which, unless otherwise stated:

- (i) evaporations were carried out by rotary evaporation *in vacuo* and work up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) all reactions were carried out under an inert atmosphere at ambient temperature, typically in the range 18-25°C, with solvents of HPLC grade under anhydrous conditions, unless otherwise stated;
- (iii) column chromatography (by the flash procedure) was performed on Silica gel 40-63 µm (Merck);
- (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) the structures of the end products of the formula (I) were generally confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; magnetic resonance chemical shift values were measured in deuterated CDCl₃ (unless otherwise stated) on the delta scale (ppm downfield from tetramethylsilane); proton data is quoted unless otherwise stated; spectra were recorded on a Varian Mercury-300 MHz, Varian Unity plus-400 MHz, Varian Unity plus-600 MHz or on Varian Inova-500 MHz spectrometer unless otherwise stated data was recorded at 400MHz; and peak multiplicities are shown as follows:

s, singlet; d, doublet; dd, double doublet; t, triplet; tt, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad; ABq, AB quartet; ABd, AB doublet, ABdd, AB doublet of doublets; dABq, doublet of AB quartets;

5

Mass spectra were recorded on one of the following instruments: LCT, QTOF, ZQ Mass spectrometer, all from Waters.

LC-MS:

- 10 Separation was performed using Agilent 1100 Series Modules or Waters 1525 pump on a Synergi MAX-RP (Phenomenex) C12 3x50 mm 4 μ m with gradient elution.

Samples were injected using Waters 2700 Sample Manager.

Mobile phases:

Generic gradients were applied from 5% to 95% acetonitrile.

- 15 Buffers containing 10 mM ammonium acetate or 5 mM ammonium formate/5mM formic acid were used.

The mass spectra were recorded with a Waters ZQ2000 or Waters ZMD equipped with an electrospray interface, switching positive and negative ionization mode. UV spectra were collected by a Agilent 1100 PDA or Waters 2996 DAD and the evaporative light scattering

- 20 (ELS) signal by a Sedere Sedex 55 or 75.

Data collection and evaluation were performed using the MassLynx software.

Accurate mass data were determined using either a LCT or QTOF MS (Waters) with leucine enkephaline (m/z 556.2771) as lockmass. Unless otherwise stated the mass ion quoted is (MH⁺).

25

Unless further details are specified in the text, analytical high performance liquid chromatography (HPLC) was performed on Prep LC 2000 (Waters), Cromasil C₈, 7 μ m, (Akzo Nobel); MeCN and de-ionised water 10 mM ammonium acetate as mobile phases, with suitable composition;

- 30 (vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), HPLC, infra-red (IR), MS or NMR analysis;
(viii) where solutions were dried sodium sulphate was the drying agent; and
(ix) the following abbreviations may be used hereinbefore or hereinafter:-

DCM	dichloromethane;
DMF	<i>N,N</i> -dimethylformamide;
TBTU	<i>o</i> -Benzotriazol-1-yl- <i>N,N,N',N'</i> -tetramethyluronium tetrafluoroborate;
EtOAc	ethyl acetate;
5 MeCN	acetonitrile;
TFA	trifluoroacetic acid;
DMAP	4-(dimethylamino)pyridine;
BSA	<i>N,O</i> -Bis(trimethylsilyl)acetamide; and
TBAF	tetrabutylammonium fluoride;
10 NMM	<i>N</i> -methyl morpholine;
TEA	triethylamine;
DBN	1,5-diazabicyclo-[4,3,0]-non-5-ene.

15

Example 1

***N*-(4-[(2*R*,3*R*)-3-[[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine**

To a stirred solution of {4-[(2*R*,3*R*)-3-[[2-(2,3-dihydro-1-benzofuran-5-yl)-2-oxoethyl]thio]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (Method 2) (15.7 mg, 0.031 mmol) in DMF (2 ml, dry) was added *N*-methylmorpholine (10 μ l, 0.091 mmol). TBTU (13.1 mg, 0.041 mmol) and additional DMF (2 ml) were added and the reaction mixture was stirred under at 30°C for 25 minutes. Glycyl-3-cyclohexyl-D-alanine (7.1 mg, 0.031 mmol) (Method 7) was added and the reaction mixture was stirred for 2 hours. The formation of the ketone of the title compound was confirmed. *M/z*: 716.57 (*M*-1). Without further purification, methanol (6 ml) and sodium borohydride (16.1 mg, 0.043 mmol) were added and the reaction mixture was stirred for 20 minutes. Ammonium acetate (85.5 mg) was added. The methanol was removed under reduced pressure and the remaining DMF-solution was purified with preparative HPLC on a C8 column. A gradient from 20 to 55 % MeCN in 0.1M NH₄OAc was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The residue was extracted between EtOAc and water, the water phase was acidified

to pH 2 with KHSO₄ (2M). The phases were separated and the organic phase was passed through a phase separator. The solvent was removed under reduced pressure. The residue was dissolved in ACN and water. After lyophilisation, the title compound was obtained. H-NMR (400 MHz, DMSO-d₆): 0.69-1.67 (m, 13H), 2.76-2.91 (m, 2H), 2.98-3.11 (m, 2H), 3.75 (d, 2H), 4.15-4.25 (m, 2H), 4.40-4.47 (m, 2H), 4.49 (s, 2H), 4.55-4.64 (m, 1H), 5.00 (b, 1H), 5.54 (b, 1H), 6.61 (dd, 1H), 6.96 (d, 3H), 7.08-7.16 (m, 3H), 7.18-7.24 (m, 2H), 7.34 (d, 2H), 8.07 (d, 1H), 8.19 (t, 1H), 12.51 (b, 1H). M/z: 718.57 (M-1).

10 Example 2

N-([4-[(2R,3R)-3-{[2-(2,3-dihydro-1H-inden-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine

To a solution of {4-[(2R,3R)-3-{[2-(2,3-dihydro-1H-inden-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (0.020 g, 0.040 mmol in DMF (1 ml) was added N-methylmorpholine (0.010 g, 0.099 mmol) followed by the addition of 3,4-dichlorophenol (0.008 g, 0.051 mmol) and TBTU (0.013 g, 0.040 mmol). After 2h, the intermediate 3,4-dichlorophenylester (3,4-dichlorophenyl {4-[(2R,3R)-3-{[2-(2,3-dihydro-1H-inden-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetate) had been formed. Glycyl-3-cyclohexyl-D-alanine (0.011 g, 0.048 mmol) and lithium chloride (0.025 g, 0.593 mmol) were added and the mixture was allowed to stir at room temperature for 2h. Methanol (1 ml) was added followed by the addition of NaBH₄ (0.022 g, 0.593 mmol). Full conversion to the corresponding alcohol had been obtained within 5 minutes. The mixture was purified through preparative HPLC using an eluent of 10-50% CH₃CN in 0.1M NH₄OAc buffer. Freeze drying of pure fractions afforded the desired compound. ¹H NMR [(CD₃)₂SO], 400 MHz] δ 0.72-1.66 (m, 13H), 1.89-1.98 (m, 2H), 2.69-2.89 (m, 6H), 3.73 (d, 2H), 4.09-4.15 (m, 1H), 4.22 (d, 1H), 4.48 (s, 2H), 4.59-4.67 (m, 1H), 4.98 (d, 1H), 6.95-7.34 (m, 11H), 7.88-7.95 (m, 1H), 8.22 (t, 1H).

30

Example 3

***N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-lysine**

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl) (53.4 mg, 0.095 mmol) in DCM (2 ml) were added EDC (24.2 mg, 0.13 mmol) and *tert*-butyl *N*⁶-(*tert*-butoxycarbonyl)-D-lysinate hydrochloride (38.8 mg, 0.11 mmol). DMAP (12.5 mg, 0.10 mmol) was added and the reaction mixture was stirred for 1 hour. The formation of the intermediate was confirmed; M/z: 849.58 (M+1) and 847.69 (M-1). Additional DCM (3 ml) and TFA (2 ml) were added and the reaction mixture was stirred for 1.5 hours. Analysis with LC-MS showed complete hydrolysis, M/z: 693.46 (M+1). The solvent was removed under reduced pressure and the residue was dissolved in methanol (4 ml). Sodium borohydride (38.8 mg, 1.03 mmol) was added and the reaction mixture was stirred for 30 minutes. Ammonium acetate (80 mg) was added. The solvent was removed under reduced pressure and the residue was purified with preparative HPLC on a C8 column. A gradient from 20 to 60 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and lyophilised to give the title compound. H-NMR (400 MHz, DMSO-d₆): 1.07-1.65 (m, 8H), 2.54-2.72 (m, 2H), 2.75-2.96 (m, 2H), 3.01-3.10 (m, 2H), 3.64-3.72 (m, 2H), 3.72-3.78 (m, 1H), 4.24 (bd, 1H), 4.44 (t, 2H), 4.49 (s, 2H), 4.55-4.61 (m, 1H), 5.00 (b, 1H), 5.74 (b, 1H), 6.58-6.64 (m, 1H), 6.93-7.00 (m, 3H), 7.08-7.16 (m, 3H), 7.17-7.24 (m, 2H), 7.34 (d, 1H), 7.46 (d, 1H), 8.38 (t, 1H). M/z: 693.52 (M-1).

Example 4

***N*-({4-[(2*R*,3*R*)-3-[[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine**

5 To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-[[2-(2,3-dihydro-1-benzofuran-5-yl)-2-oxoethyl]thio]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (53.4 mg, 0.095 mmol) in DMF (5 ml) were added *N*-methylmorpholine (35 μ l, 0.32 mmol) and 3,4-dichlorophenol (19 mg, 0.12 mmol). TBTU (35 mg, 0.11 mmol) was added and the reaction mixture was stirred overnight. 3-methyl-D-valine (14.4 mg, 0.11 mmol) and lithium chloride
10 (35.7 mg, 0.84 mmol) were added and the reaction mixture was stirred for 2.5 hours. The formation of the ketone of the title compound was confirmed, *M/z*: 678.24 (*M*+1) and 676.26 (*M*-1). Methanol (4 ml) and sodium borohydride (94.7 mg, 2.5 mmol) were added and the reaction mixture was stirred for 30 minutes. Ammonium acetate (115 mg) was added and some of the solvent was removed under reduced pressure. The remaining DMF-solution was
15 purified with preparative HPLC on a C8 column. A gradient from 20 to 60 % MeCN in 0.1M NH₄OAc was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was diluted with DCM. The water phase was acidified with KHSO₄ (2M) to pH ca 2. The phases were separated and the organic phase was passed through a phase separator. The solvent was removed under reduced
20 pressure. The residue was dissolved in MeCN and water. After lyophilisation the title compound was obtained. ¹H-NMR (400 MHz, DMSO-*d*₆): 0.84-0.89 (s, 9H), 2.75-2.92 (m, 2H), 2.97-3.11 (m, 2H), 3.79 (d, 2H), 4.01 (bd, 1H), 4.21-4.27 (m, 1H), 4.44 (t, 2H), 4.49 (s, 2H), 4.55-4.65 (m, 1H), 5.00 (b, 1H), 5.48 (b, 1H), 6.58-6.64 (m, 1H), 6.92-7.00 (m, 3H), 7.08-7.16 (m, 3H), 7.17-7.24 (m, 2H), 7.34 (d, 2H), 7.57-7.91 (m, 1H), 8.24 (bt, 1H). *M/z*:
25 678.31(*M*-1).

Example 5

N-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-*b,b*-dimethyl-*D*-phenylalanine

5 To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl) (55.6 mg, 0.098 mmol) in DMF (4 ml) were added *N*-methylmorpholine (45 μ l, 0.41 mmol) and 3,4-dichlorophenol (21 mg, 0.13 mmol). TBTU (39 mg, 0.12 mmol) was added and the reaction mixture was stirred overnight. β,β -dimethyl-*D*-phenylalanine trifluoroacetate (37.4mg, 0.12 mmol) and lithium chloride (45 mg, 1.06 mmol) were added and the reaction mixture was stirred for 3 hours. The formation of the ketone of the title compound was confirmed; M/z: 740.25 (M+1) and 738.32 (M-1). Methanol (4 ml) and sodium borohydride (94.7 mg, 2.5 mmol) were added and the reaction mixture was stirred for 1 hour. Ammonium acetate (115 mg) was added and some of the solvent was removed under reduced pressure. The remaining

10 DMF-solution was purified with preparative HPLC on a C8 column. A gradient from 20 to 70 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was diluted with DCM. The water phase was acidified with KHSO₄ (2M) to pH ca 2. The phases were separated and the organic phase was passed through a phase separator. The solvent was

20 removed under reduced pressure. The residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. H-NMR (400 MHz, DMSO-d₆): 1.27 (s, 3H), 1.30 (s, 3H), 2.79-2.89 (m, 2H), 2.97-3.11 (m, 2H), 3.58-3.82 (m, 2H), 4.22 (b, 1H), 4.39-4.48 (m, 4H), 4.59 (b, 2H), 5.00 (b, 1H), 5.43 (b, 1H), 6.58-6.63 (m, 1H), 6.91-6.99 (m, 3H), 7.06-7.15 (m, 4H), 7.17-7.25 (m, 4H), 7.27-7.36 (m, 4H), 7.82 (b, 1H), 8.18 (t, 1H). M/z: 740.35

25 (M-1).

Example 6

N-{[4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-{[(2*R*)-2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]thio}-4-oxoazetidin-2-yl]phenoxy}acetyl]glycyl-3-cyclohexyl-*D*-alanine

30

To a solution of [4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-{[(2*R* or *S*)-2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]thio}-4-oxoazetidin-2-yl]phenoxy]acetic acid (0.021 g, 0.04 mmol) in DMF (0.5 ml) under an atmosphere of nitrogen was added *N*-methylmorpholine

(0.010 g, 0.10 mmol) followed by the addition of 4-chlorophenol (0.007 g, 0.05 mmol) and TBTU (0.013 g, 0.04 mmol). After 1h, full conversion to the 4-chlorophenylester intermediate (4-chlorophenyl [4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-{[(2*R*)-2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetate) had been
 5 obtained. Glycyl-3-cyclohexyl-D-alanine (0.012 g, 0.05 mmol) and lithium chloride (0.026 g, 0.60 mmol) were added and the mixture was allowed to stir at room temperature for three days. Full conversion to the desired product had now been obtained. The mixture was purified through preparative HPLC using an eluent of 0-45% CH₃CN in 0.1M NH₄OAc buffer. Freeze drying of pure fractions afforded the desired compound. ¹H NMR [(CD₃)₂SO], 400 MHz]
 10 δ 0.70-1.68 (m, 17H), 2.58-2.66 (m, 4H), 2.82 (dd, 1H), 2.86 (dd, 1H), 3.73 (d, 2H), 4.09-4.15 (m, 1H), 4.23 (d, 1H), 4.48 (s, 2H), 4.56 (t, 1H), 4.98 (d, 1H), 6.90-7.34 (m, 11H), 7.92 (d, 1H), 8.22 (t, 1H).

15 **Example 7**

***N*-({4-[(2*R*,3*R*)-3-{[(2*R or S*)-2-(2,3-dihydro-1*H*-inden-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine**

The titled compound was obtained as a pure diastereomer upon separation from a 50:50
 20 diastereomeric mixture of *N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1*H*-inden-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine using the following conditions: Column R,R-Whelk-O1, 250 X 21.2 mm, particle size 10 μm, mobile phase Heptane/EtOH/HCO₂H 70/30/0.1, flow 15 ml/min, detection 254 nm, sample concentration 9.5 mg/ml in heptane/ethanol 70/30. The titled
 25 diastereomer is the second eluting one in this system. ¹H NMR [(CD₃)₂SO], 400 MHz] δ 0.72-1.69 (m, 13H), 1.89-1.98 (m, 2H), 2.72-2.90 (m, 6H), 3.75 (d, 2H), 4.14-4.21 (m, 1H), 4.22 (d, 1H), 4.48 (s, 2H), 4.58-4.64 (m, 1H), 4.98 (d, 1H), 6.94-7.34 (m, 11H), 8.02-8.06 (m, 1H), 8.17-8.23 (m, 1H).

30 **Example 8**

***N*-({4-[(2*R*,3*R*)-3-{[(2*R or S*)-2-(2,3-Dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine ammoniate**

N-({4-[(2*R*,3*R*)-3-{[(2*R*)-2-{[*tert*-Butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine (16 mg, 0.020 mmol) was dissolved in 2 ml dry THF under inert atmosphere. HOAc (0.011 ml, 0.19 mmol) and TBAF (1M in THF, 0.200 ml, 0.20 mmol) were added and the mixture was stirred over the weekend. The solvent was evaporated and the residue was purified by preparative HPLC on a C8 column (300 x 25 mm) using a gradient from 20% to 35% MeCN in 0.1 M NH₄OAc buffer as eluent. The product fraction was lyophilized to yield 13.5 mg. The solid was dissolved in MeOH (1 ml) and run through a cation-exchange column (400 mg ISOLUTE[®] SCX-column, IST) pre-equilibrated with ammonia in MeOH. MeOH was used as eluent and the product fraction was concentrated, diluted with water and lyophilized. The title compound was obtained. *M/z*: 718 (M-1). ¹H-NMR (400 MHz, DMSO-*d*₆): δ 0.70-0.92 (m, 2H), 1.01-1.20 (m, 3H), 1.21-1.44 (m, 2H), 1.46-1.77 (m, 6H), 2.82-2.96 (m, 2H), 3.10 (t, 2H), 3.75 (d, 2H), 3.99-4.09 (m, 1H), 4.27 (d, 1H), 4.48 (t, 2H), 4.53 (s, 2H), 4.62 (t, 1H), 5.04 (d, 1H), 6.65 (d, 1H), 6.97-7.04 (m, 3H), 7.11-7.20 (m, 3H), 7.21-7.28 (m, 2H), 7.38 (d, 2H), 7.70-7.79 (m, 1H), 8.29 (t, 1H).

Example 9

N-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine

20

To a solution of *N*-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine (8 mg, 0.010 mmol) in THF (2 ml, dry) were added acetic acid (6 μl, 0.104 mmol) and TBAF (1M in THF, 104 μl, 0.104 mmol). The reaction mixture was stirred over the weekend. Additional TBAF (1M in THF 5.4 μl, 0.0054 mmol) was added and the reaction mixture was stirred overnight. The solvent was removed under reduced pressure and the residue was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 65 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and most of the MeCN was removed under reduced pressure. The residue was lyophilised to give a white solid. The obtained compound was dissolved in MeOH and run through a cation-exchange column (400 mg SCX, SPE-product). The column was pre-equilibrated with 25 % ammonia solution: MeOH (1:3, 3 ml), and washed with MeOH (3 ml). This procedure was repeated once more and the solvent was

removed under reduced pressure. The residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. H-NMR (400 MHz, DMSO-d₆): 0.81 (s, 9H), 2.79-2.92 (m, 2H), 3.03-3.10 (m, 2H), 3.63-3.89 (m, 3H), 4.26 (b, 1H), 4.44 (t, 2H), 4.50 (s, 2H), 4.59 (t, 1H), 4.99 (d, 1H), 6.61 (d, 1H), 6.94-6.99 (m, 3H), 7.08-7.16 (m, 3H), 7.17-7.23 (m, 2H), 7.33 (d, 2H), 8.31 (bs, 1H). M/z: 678.34 (M-1).

Example 10

N-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine

10

To a solution of *N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-[(*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine (20.0 mg, 0.025 mmol) in THF (2 ml, dry) were added acetic acid (10.4 μ l, 0.250 mmol) and TBAF (1M in THF, 268 μ l, 0.268 mmol). The reaction mixture was stirred overnight. Additional TBAF (25.6 μ l, 0.026 mmol) was added and the reaction mixture was stirred overnight. The solvent was removed under reduced pressure. The residue was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 60 % MeCN in a 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and most of the MeCN was removed under reduced pressure. The residue was acidified with KHSO₄ (2M) to pH 3 and extracted from DCM. The organic phase was concentrated. The residue was dissolved in MeOH and run through a cation-exchange column (400 mg SCX, SPE-product). The column was pre-equilibrated with 25 % ammonia solution:MeOH (1:3; 3 ml) and washed with MeOH (3 ml). The solvent was removed under reduced pressure. The residue was dissolved in MeCN and water and lyophilised to give the title compound. H-NMR (400 MHz, DMSO-d₆): 0.72-0.76 (m, 6H), 1.94-2.02 (m, 1H), 2.79-2.91 (m, 2H), 3.01-3.10 (m, 2H), 3.78 (d, 2H), 3.98-4.07 (m, 1H), 4.22 (d, 1H), 4.44 (t, 2H), 4.49 (s, 2H), 4.58 (t, 1H), 5.00 (d, 1H), 5.44 (bs, 1H), 6.62 (d, 1H), 6.93-7.00 (m, 3H), 7.08-7.15 (m, 3H), 7.17-7.24 (m, 2H), 7.34 (d, 2H), 7.84 (d, 1H), 8.23 (t, 1H). M/z: 664.38 (M-1).

30 Example 11

N-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-4-cyano-D-phenylalanine

To a solution of *N*-({4-[(2*R*,3*R*)-3-{{(2*R* or *S*)-2-[[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-4-cyano-D-phenylalanine (22.2 mg, 0.026 mmol) in THF (2 ml, dry) were added acetic acid (15 μ l, 0.260 mmol) and TBAF (1M in THF, 273 μ l, 0.273 mmol). The reaction mixture was stirred over the weekend. The solvent was removed under reduced pressure. The residue was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 75 % MeCN in a 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected. Most of the MeCN was removed under reduced pressure and the residue was lyophilised to give the title compound. H-NMR (500 MHz, DMSO-d₆): 2.82-2.98 (m, 4H), 3.05-3.16 (m, 2H), 3.64-3.79 (m, 2H), 4.24 (bd, 1H), 4.42-4.49 (m, 3H), 4.50 (s, 2H), 4.61 (bt, 1H), 5.03 (bd, 1H), 5.46 (bs, 1H), 6.64 (d, 1H), 6.94-7.02 (m, 4H), 7.11-7.17 (m, 2H), 7.20-7.25 (m, 2H), 7.38 (dd, 4H), 7.70 (d, 2H), 8.19-8.24 (m, 2H). M/z: 737 (M-1).

15 **Example 12**

N-({4-[(2*R*,3*R*)-3-{{2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-*N*⁶,*N*⁶-dimethyl-L-lysine.

To a solution of *N*-({4-[(2*R*,3*R*)-3-{{(2*R*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-*N*⁶,*N*⁶-dimethyl-L-lysine (11.0 mg, 0.013 mmol) in MeCN (1 ml) were added scandium tris(trifluoromethanesulfonate) (0.5 mg, 0.00102 mmol) and water (2 μ l, 0.131 mmol). The reaction mixture was stirred for 3 hours. Additional Sc(OTf)₃ (0.7 mg, 0.00142 mmol) and water (2 μ l, 0.131 mmol) were added and the mixture was stirred for 1 hour. Additional Scandium tris(trifluoromethanesulfonate) (6.0 mg, 0.01219 mmol) and water (4 μ l, 0.262) were added and the reaction mixture was stirred for 1 hour. Ammonium acetate buffer (0.1M, 1 ml) was added. The resulting solution was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 43 % MeCN was used as eluent. The pure fractions were collected and most of the MeCN was removed under reduced pressure. The residue was lyophilised to give the title compound. H-NMR (500 MHz, DMSO-d₆): 1.21-1.31 (m, 2H), 1.33-1.44 (m, 2H), 1.51-1.60 (m, 1H), 1.63-1.71 (m, 1H), 2.16 (s, 6H), 2.25 (bs, 2H), 2.81-2.94 (m, 2H), 3.01-3.15 (m, 2H), 3.78 (d, 2H), 4.07 (bs, 1H), 4.25 (d, 0.5H) 4.26 (d, 0.5H), 4.44-4.50 (m, 2H), 4.52 (s, 2H), 4.59-4.66 (m, 1H), 5.01-5.05 (b, 1H), 6.64 (dd, 1H), 6.97-

7.02 (m, 3H), 7.11-7.18 (m, 3H), 7.21-7.26 (m, 2H), 7.37 (d, 2H), 7.98 (bs, 1H), 8.26 (t, 1H).
M/z: 721.40 (M-1)

Example 13

5 *N*-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline

To a solution of *N*-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-{*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline (10.3 mg, 0.013 mmol) in THF (2 ml, dry)
10 were added acetic acid (8 μ l, 0.140 mmol) and TBAF (1M in THF, 145 μ l, 0.145 mmol) were added and the reaction mixture was stirred over the weekend. Additional acetic acid (4 μ l, 0.070 mmol) and TBAF (1M in THF, 73 μ l, 0.073 mmol) were added and the reaction mixture was stirred overnight. Additional acetic acid (8 μ l, 0.140 mmol) and TBAF (1M in
15 THF, 145 μ l, 0.145 mmol) were added and the reaction mixture was stirred overnight. The solvent was removed under reduced pressure. The residue was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 70 % MeCN in a 0.1M NH₄OAc was used as eluent. The pure fractions were collected and most of the MeCN was removed under reduced pressure. The remaining was acidified with KHSO₄ (2M) to pH 3 and
20 extracted from DCM. The organic phase was concentrated. The residue was dissolved in MeOH (1 ml) and run through a cation-exchange column (400 mg SCX, SPE-product). The column was pre-equilibrated with 25 % ammonia solution:MeOH (1:3, 3 ml) and washed with MeOH (3 ml). The solvent was removed under reduced pressure. The residue was dissolved in MeCN and water and lyophilised to give the title compound. H-NMR (400 MHz, DMSO-
25 d₆): 0.78 (d, 3H), 0.85 (d, 3H), 1.26 (s, 3H) 1.94-2.02 (m, 1H) 2.79-2.90 (m, 2H), 3.03-3.10 (m, 2H), 3.72 (d, 2H), 4.21 (d, 1H), 4.44 (t, 2H), 4.49 (s, 2H), 4.58 (bt, 1H), 5.00 (d, 1H), 5.43 (bs, 1H), 6.61 (d, 1H), 6.93-6.99 (m, 3H), 7.08-7.15 (m, 3H), 7.17-7.23 (2H), 7.34 (d, 2H), 7.77 (bs, 1H), 8.19 (bt, 1H). M/z: 678.32 (M-1).

30 **Example 14**

N-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycylglycine

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycylglycine (22.0 mg, 0.030 mmol)

- 5 in MeCN were added scandium tris(trifluoromethanesulfonate) (0.1 mg, 2 μ mol) and water (3 μ l). The reaction mixture was stirred for 1h. Additional (0.5 mg, 10.2 μ mol) was added. The reaction mixture was stirred overnight. LC-MS showed complete desilylation. NH₄OAc buffer (0.1M, 1 ml) was added. The solution was purified with preparative HPLC on a C8 column. A gradient from 20 to 70% MeCN in a 0.1 M NH₄OAc buffer was used as eluent.
- 10 The pure fractions were collected and most of the MeCN was removed under reduced pressure. The residue was extracted from DCM. The water phase was acidified to pH 3 with KHSO₄ (2M). The phases were separated and the organic phase was concentrated. The residue was dissolved in ACN and water and lyophilised to give the title compound. H-NMR (400 MHz, DMSO-*d*₆): 2.77-2.92 (m, 2H), 2.99-3.11 (m, 2H), 3.67 (b, 2H), 3.75 (d, 2H),
- 15 4.21-4.25 (m, 1H), 4.44 (dt, 2H), 4.49 (s, 2H), 4.55-4.64 (m, 1H), 5.00 (b, 1H), 5.45 (b, 1H), 6.61 (dd, 1H), 6.96 (d, 3H), 7.06-7.16 (m, 3H), 7.17-7.23 (m, 2H), 7.34 (d, 2H), 8.08 (b, 1H), 8.28 (t, 1H). M/z: 622.23 (M-1).

20

Example 15

(*R*)-3-Cyclohexyl-2-[2-(2-{4-[(2*R*,3*R*)-3-[2-(2,3-dihydro-benzofuran-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetylamino)-acetylamino]-propionic acid

25


- To a solution of {4-[(2*R*,3*R*)-3-[2-(2,3-dihydro-benzofuran-6-yl)-2-oxo-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid (33 mg, 0.065 mmol) in DMF (3 mL) at RT was added *N*-methylmorpholine (22 μ l, 0.198 mmol) and TBTU (22 mg, 0.069
- 30 mmol). The mixture was stirred for 30 min before (*R*)-2-(2-amino-acetylamino)-3-cyclohexyl-propionic acid (15 mg, 0.066 mmol) was added. After 2 h 30 min, the reaction was quenched by the addition of water (1 mL). The mixture was diluted with MeOH (1 mL) and then added NaBH₄ (35 mg, 0.925 mmol). After 15 min, the reaction was quenched by the addition of 1M HCl (3 mL) and the resulting solution was purified by preparative HPLC

using a gradient of 0-60 % MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

$^1\text{H-NMR}$ (DMSO, 400 MHz): δ 0.71-0.95 (m, 2H), 1.00-1.72 (m, 11 H), 2.80-2.90 (m, 2H), 3.05-3.15 (m, 2H), 3.77 (d, 2H), 4.12-4.21 (m, 1H), 4.24-4.29 (m, 1H), 4.42-4.55 (m, 4H), 4.59-4.68 (m, 1H), 4.99-5.05 (m, 1H), 6.67-6.77 (m, 2H), 6.95-7.02 (m, 2H), 7.05-7.27 (m, 5H), 7.32-7.41 (m, 2H), 7.94-8.02 (m, 1H), 8.20-8.28 (m, 1H).

10 The following compounds could be prepared by the procedure of Example 8, but wherein different protecting groups may be used.

15



X	Y	Y ₁	R ¹	R ²	R ³	R ⁴	R ⁵
CH ₂ CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-CN	H	H	F
CH ₂ CH ₂	CH ₂	O	H	cyclohexyl	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ cyclohexyl	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	F
CH ₂ CH ₂	CH ₂	O	H	C(CH ₃) ₂ C ₆ H ₅	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH(CH ₃) ₂	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH(CH ₃) ₂	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH(CH ₃) ₂	CH ₃	H	F
CH ₂ CH ₂	CH ₂	O	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	² H	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ SC(CH ₃) ₃	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	F
CH ₂ CH ₂	CH ₂	O	H	C(CH ₃) ₃	H	H	F
CH ₂ CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-OH	H	H	H

CH ₂ CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-CN	H	H	H
CH ₂ CH ₂	CH ₂	O	H	cyclohexyl	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH ₂ cyclohexyl	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂ CH ₂	CH ₂	O	H	C(CH ₃) ₂ C ₆ H ₅	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH(CH ₃) ₂	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH(CH ₃) ₂	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH(CH ₃) ₂	CH ₃	H	H
CH ₂ CH ₂	CH ₂	O	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH H	
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	² H	H
CH ₂ CH ₂	CH ₂	O	H	CH ₂ SC(CH ₃) ₃	H	H	H
CH ₂ CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	H
CH ₂ CH ₂	CH ₂	O	H	C(CH ₃) ₃	H	H	H
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅	H	H	F
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-OH	H	H	F
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-CN	H	H	F
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	F
CH ₂	CH ₂	O	H	CH ₂ CH(CH ₃) ₂	H	H	F
CH ₂	CH ₂	O	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH F	
CH ₂	CH ₂	O	H	CH ₂ SC(CH ₃) ₃	H	² H	F
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	F
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅	H	H	H
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-OH	H	H	H
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-CN	H	H	H
CH ₂	CH ₂	O	H	cyclohexyl	H	H	H
CH ₂	CH ₂	O	H	CH ₂ cyclohexyl	H	H	H
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂	CH ₂	O	H	C(CH ₃) ₂ C ₆ H ₅	H	H	H
CH ₂	CH ₂	O	H	CH(CH ₃) ₂	H	H	H
CH ₂	CH ₂	O	H	CH ₂ CH(CH ₃) ₂	H	H	H
CH ₂	CH ₂	O	H	CH(CH ₃) ₂	CH ₃	H	H
CH ₂	CH ₂	O	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH H	
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	² H	H
CH ₂	CH ₂	O	H	CH ₂ SC(CH ₃) ₃	H	H	H
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	H
CH ₂	CH ₂	O	H	C(CH ₃) ₃	H	H	H
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-OH	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-CN	H	H	Cl
CH ₂	CH ₂	O	H	cyclohexyl	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ cyclohexyl	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	Cl
CH ₂	CH ₂	O	H	C(CH ₃) ₂ C ₆ H ₅	H	H	Cl

- 74 -

CH ₂	CH ₂	O	H	CH(CH ₃) ₂	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ CH(CH ₃) ₂	H	H	Cl
CH ₂	CH ₂	O	H	CH(CH ₃) ₂	CH ₃	H	Cl
CH ₂	CH ₂	O	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH	Cl
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	² H	Cl
CH ₂	CH ₂	O	H	CH ₂ SC(CH ₃) ₃	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	Cl
CH ₂	CH ₂	O	H	C(CH ₃) ₃	H	H	Cl
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅	H	H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-OH	H	H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ C ₆ H ₅ -p-CN	H	H	CH ₃
CH ₂	CH ₂	O	H	cyclohexyl	H	H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ cyclohexyl	H	H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	CH ₃
CH ₂	CH ₂	O	H	C(CH ₃) ₂ C ₆ H ₅	H	H	CH ₃
CH ₂	CH ₂	O	H	CH(CH ₃) ₂	H	H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ CH(CH ₃) ₂	H	H	CH ₃
CH ₂	CH ₂	O	H	CH(CH ₃) ₂	CH ₃	H	CH ₃
CH ₂	CH ₂	O	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH	CH ₃
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	² H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ SC(CH ₃) ₃	H	H	CH ₃
CH ₂	CH ₂	O	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	CH ₃
CH ₂	CH ₂	O	H	C(CH ₃) ₃	H	H	CH ₃

Methods for preparing starting materials***N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine**

To a stirred solution of {4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (166.20 mg, 0.33 mmol) in DCM
 10 (10 ml) were added EDC (71.5 mg, 0.37 mmol) and *tert*-butyl glycinate hydrochloride (65.8 mg, 0.39 mmol). DMAP (21.7 mg, 0.18 mmol) was added and the reaction mixture was stirred for 3.5 hours. The formation of the *tert*-butyl ester of the title compound was confirmed, M/z: 619 (M-1). TFA (5 ml) was added and the reaction mixture was stirred for 1
 15 hour and 15 minutes. LC-MS showed complete hydrolysis. The solvent was removed under reduced pressure, toluene was used to assist the removal of TFA. The residue was purified with preparative HPLC on a C8 column. A gradient from 20 to 65 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The MeCN was removed under reduced pressure and the

- 75 -

remaining water solution was diluted with DCM. The water phase was acidified to pH ca 2 with KHSO_4 (2M). The phases were separated and the organic phase was passed through a phase separator. The solvent was removed under reduced pressure to give the title compound.

H-NMR (400 MHz, DMSO-d_6): 3.17 (t, 2H), 3.77(d, 2H), 4.19-4.28 (m, 2H) 4.29 (d, 1H),
5 4.48 (s, 2H), 4.60 (t, 2H), 5.13 (d, 1H), 6.81 (d, 1H), 6.95 (d, 2H), 7.06-7.15 (m, 2H), 7.16-7.23 (m, 2H), 7.33 (d, 2H), 7.70-7.76 (m, 1H), 7.79 (s, 1H), 8.34 (t, 1H), 12.55 (bs, 1H). M/z: 565.20 (M+1) and 563.22 (M-1).

5 **{4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid**

To a stirred solution of *tert*-butyl (4-{(2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl}phenoxy)acetate (50.0 mg, 0.090 mmol) in acetone (6 ml) and
10 water (0.8 ml) was added triphenylphosphine (33.3 mg, 0.013 mmol). The reaction mixture was stirred for 15 minutes. The solvent was removed under reduced pressure and the crude thiol was dissolved in DCM (12 ml). Et₃N, (30 μ l, 0.22 mmol) was added. After 5 minutes, 2-chloro-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone (37.2 mg, 0.19 mmol) was added and the reaction mixture was stirred overnight. Additional triphenylphosphine (11.6 mg, 0.04 mmol),
15 Et₃N (10 μ l, 0.07 mmol) and 2-chloro-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone (7.2 mg, 0.04 mmol) were added and the reaction mixture was stirred for 1 hour. The formation of the *tert*-butyl ester of the title compound was confirmed. M/z: 564.24 (M+1) and 562.21 (M-1). To the DCM solution of the previous reaction was added TFA (6 ml) and the mixture was stirred for 1 hour. The solvent was removed under reduced pressure and the residue was
20 purified with preparative HPLC on a C8 column. A gradient from 20 to 70% ACN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was diluted with additional water and EtOAc. The water phase was acidified with KHSO₄ (2M) to pH 2. The phases were separated and the organic phase was passed through a phase separator and concentrated. The
25 oily residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. H-NMR (400 MHz, DMSO-d₆): 3.17 (t, 2H), 4.23 (ABq, 2H), 4.28 (d, 1H), 4.52 (b, 2H), 4.59 (t, 2H), 5.11 (d, 1H), 6.78-6.88 (m, 3H), 7.09-7.15 (m, 2H) 7.16-7.22 (m, 2H), 7.30 (d, 2H), 7.71-7.76 (m, 1H), 7.79 (s, 1H). M/z: 508.13 (M+1) and 506.22 (M-1).

30

(4*S*)-3-[[4-Methoxybenzyl]thio]acetyl}-4-phenyl-1,3-oxazolidin-2-one

[(4-Methoxybenzyl)thio]acetic acid (1.3 g, 6.1 mmol) was dissolved in dry CH₂Cl₂ (40 ml) and given 0°C. N,N'-Dicyclohexylcarbodiimide (DCC, 6.1 g, 6.1 mmol) and 4-

(dimethylamino)pyridine (DMAP, 1.6 g, 12.9 mmol) were added and the mixture was stirred for 30 minutes. (S)-(+)-4-Phenyl-2-oxazolidinone (1.0 g, 6.1 mmol) was added and the mixture was stirred at room temperature for 24 hours. The mixture was filtrated, concentrated under reduced pressure and purified by flash-chromatography (Hex : EtOAc 8:2 then 1:1). This
5 afforded the title compound as a white solid.

¹H-NMR (CDCl₃, 200 MHz): δ 3.46-3.59 (m, 3H), 3.74-3.76 (m, 4H), 4.23-4.28 (m, 1H), 4.68 (t, *J* = 8.8 Hz, 1H), 5.38-5.42 (m, 1H), 6.78 (d, *J* = 8.6 Hz, 2H), 7.14 (d, *J* = 8.6 Hz, 2H), 7.32-7.40 (m, 5H).

10

***tert*-Butyl (4-((1*R*)-1-[(4-fluorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl)phenoxy)acetate**

15

TiCl₄ (1M in CH₂Cl₂, 12.6 mL, 12.6 mmol) was added to a solution of tetraisopropyl orthotitanate (1.24 mL, 4.2 mmol) in CH₂Cl₂ (80 mL) held at 0°C under inert atmosphere. The mixture was stirred for 15 minutes, then (4*S*)-3-[[4-methoxybenzyl]thio]acetyl-4-phenyl-1,3-oxazolidin-2-one (6.0 g, 16.8 mmol) in dry CH₂Cl₂ (60 mL) was added dropwise over 30
20 minutes and the mixture was stirred for ten minutes. Then *tert*-butyl (4-[(*E*)-[(4-fluorophenyl)imino]methyl]phenoxy)acetate (11.1 g, 33.6 mmol) in dry CH₂Cl₂ (60 mL) was added dropwise over 30 minutes, the mixture was given -40°C and stirred for 20 minutes. Ethyl diisopropyl amine (5.8 mL, 33.6 mmol) in 20 mL CH₂Cl₂ was added dropwise over 20 minutes and the mixture was stirred at -40°C for 90 minutes. The mixture was then given -
25 78°C, added isopropanol (50 mL) and slowly given room temperature over two hours. H₂O (100 mL) was added and the mixture was stirred for 20 minutes at room temperature and then extracted twice with diethyl ether. The combined organic layer was washed with water, dried (MgSO₄) and concentrated under reduced pressure. The crude product was dissolved in methanol and a precipitate formed. Filtration and drying the title compound.

30

¹H-NMR (CDCl₃, 200 MHz): δ 1.5 (s, 9H), 3.65 (s, 1H), 3.8 (s, 3H), 4.1 (m, 1H), 4.4-4.6 (m, 4H), 5.0-5.2 (m, 2H), 5.4 (m, 1H), 6.4-6.6 (m, 2H), 6.7-7.4 (m, 15H).

***tert*-Butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(4-methoxybenzyl)thio]-4-oxoazetidin-2-yl)phenoxy)acetate**

5

tert-Butyl (4-((1*R*)-1-[(4-fluorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl)phenoxy)acetate (9.3 g, 13.5 mmol) was dissolved in dry toluene (500 mL) and heated to 90°C under inert atmosphere. N,O-

Bis(trimethylsilyl)acetamide (BSA, 9.9 mL, 40.6 mmol) was added and the mixture was
10 stirred at 90°C for one hour. The mixture was then given 45°C and tetrabutylammonium fluoride (TBAF, 1 g) was added. The mixture was stirred at 45°C for 24 hours. After cooling, the mixture was concentrated under reduced pressure and purified by flash-chromatography (Hex : EtOAc 6:1 then 5:1 then 4:1). This afforded the title compound.

15 ¹H-NMR (CDCl₃, 200 MHz): δ 1.5 (s, 9H), 3.7 (s, 3H), 3.9 (m, 3H), 4.5 (m, 3H), 6.7 (d, 2H), 6.8-7.0 (m, 4H), 7.0-7.2 (m, 6H).

20

***tert*-Butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl)phenoxy)acetate**

25

tert-Butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(4-methoxybenzyl)thio]-4-oxoazetidin-2-yl)phenoxy)acetate (2.54 g, 4.86 mmol) was dissolved in CH₂Cl₂ (60 mL) and given 0°C under inert atmosphere. 3-nitro-2-pyridinesulfonyl chloride (1.11 g, 5.82 mmol) was added and the mixture was stirred for two hours at 0°C, the one hour at room temperature.

30 Concentration under reduced pressure and purification by flash-chromatography (Hex : EtOAc 2:1) afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 1.6 (s, 9H), 4.3 (d, 1H), 4.5 (s, 2H), 5.2 (d, 1H), 6.8-7.0 (m, 4H), 7.1-7.3 (m, 4H), 7.4 (m, 1H) 8.5 (d, 1H), 8.9 (d, 1H).

5 Glycyl-3-cyclohexyl-D-alanine

N-(*tert*-butoxycarbonyl)glycine (2.0 g, 11.4 mmol) and DIPEA (4.0 g, 31 mmol) were dissolved in methylene chloride (25 ml). TBTU (4.1 g, 12.8 mmol) was added and the mixture was stirred for 15 min at room temperature. 3-cyclohexyl-D-alanine (2.1 g, 12.2 mmol) was added and the reaction mixture was stirred over night at room temperature. The reaction mixture was transferred to a separation funnel and was then extracted with a water/acetic acid solution (100ml 5% acetic acid). The organic layer was separated and evaporated under reduced pressure. The residue was dissolved in formic acid (20 ml) and the mixture was stirred over night at 40 °C. The formic acid was removed under reduced pressure. The residue was washed with water (50 ml) and then stirred in acetone (25 ml) for 1 h at room temperature. The solid material was filtered off and washed with acetone (20 ml). The title compound was obtained.

¹H-NMR, 300 MHz, CD₃COOD): 0.8-1.9 (m, 13H), 3.9-4.1 (m, 2H), 4.55-4.65 (m, 1H)

tert-butyl (4-[(*E*)-[(4-fluorophenyl)imino]methyl]phenoxy)acetate

tert-Butyl (4-formylphenoxy)acetate (93.7 g, 0.40 mol) was dissolved in dry toluene (200 mL), added 4-fluoroaniline (38.1 mL, 0.40 mol) and *p*-toluene sulfonic acid (cat, ~1g). The mixture was refluxed in a Dean-Stark apparatus for 2 hours, cooled at an icebath and a precipitate was formed. The precipitate was filtered, washed with cold heptane and dried to afford the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 1.6 (s, 9H), 4.8 (s, 2H), 7.0-7.4 (m, 6H), 7.9 (d, 2H), 8.4 (s, 1H).

{4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1*H*-inden-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid

5

To a solution of *tert*-butyl (4-{(2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl]phenoxy)acetate (0.100 g, 0.179 mmol) in acetone (2 ml) and water (0.5 ml) was added triphenylphosphine (0.047 g, 0.179 mmol). After 30 minutes, the mixture was concentrated. To the residue was added dichloromethane (3 ml) followed by the addition of triethylamine (0.073 g, 0.717 mmol) and 2-bromo-1-(2,3-dihydro-1*H*-inden-5-yl)ethanone (0.107 g, 0.448 mmol). After 30 minutes, full conversion of the thiol had been achieved. The mixture was concentrated and to the residue was added formic acid (2 g) and trifluoroacetic acid (0.2 g). The mixture was allowed to stir at room temperature for 3h. The crude product was purified through preparative HPLC using an eluent of 10-50% CH₃CN in 0.1M NH₄OAc buffer. Freeze drying of pure fractions afforded the desired compound. ¹H NMR [(CD₃)₂SO], 400 MHz] δ 1.96-2.04 (m, 2H), 2.83-2.89 (m, 4H), 4.23-4.34 (m, 5H), 5.09 (d, 1H), 6.76-7.74 (m, 11H).

[4-((2*R*,3*R*)-1-(4-fluorophenyl)-4-oxo-3-{[2-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]thio}azetidin-2-yl)phenoxy]acetic acid

20

The titled compound above was prepared using the same procedure as that used for the synthesis of {4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1*H*-inden-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid but using 2-bromo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanone instead of 2-bromo-1-(2,3-dihydro-1*H*-inden-5-yl)ethanone. ¹H NMR [(CD₃)₂SO], 400 MHz] δ 1.66-1.75 (m, 4H), 2.66-2.77 (m, 4H), 4.22-4.31 (m, 3H), 4.62 (s, 2H), 5.11 (d, 1H), 6.86-7.61 (m, 11H).

30

[4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-{[(2*R* or *S*)-2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetic acid

To a solution of [4-((2*R*,3*R*)-1-(4-fluorophenyl)-4-oxo-3-{[2-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]thio}azetidin-2-yl)phenoxy]acetic acid (0.105 g, 0.20 mmol) in MeOH (3 ml) was added NaBH₄ (0.015 g, 0.40 mmol). After 5 minutes, the resulting two diastereomeric alcohols (50:50 mixture) were separated through preparative HPLC using a C-8 column and CH₃CN in 0.1M NH₄OAc buffer (0-40%) as eluent. Freeze drying of pure fractions afforded the desired pure diastereomer (the first eluting one. ¹H NMR [(CD₃)₂SO], 400 MHz] δ 1.62-1.70 (m, 4H), 2.56-2.67 (m, 4H), 2.80-2.89 (m, 2H), 4.22 (d, 1H), 4.53-4.59 (d, 1H), 4.62 (s, 2H), 4.98 (d, 1H), 5.43 (d, 1H), 6.88-7.32 (m, 11H).

N-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine

To a stirred solution of {4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (317.0 mg, 0.51 mmol) and methyl glycinate hydrochloride (77.5 mg, 0.62 mmol) in DCM (3 ml, dry) was added *N*-methylmorpholine (168 μl, 1.52 mmol). The reaction mixture was stirred for five minutes. TBTU (194 mg, 0.604 mmol) was added and the reaction mixture was stirred for 2 hours. The formation of the methylester of the title compound was confirmed; M/z: 693 (M-1). The solvent was removed under reduced pressure. The residue was suspended in MeCN (6 ml). Triethylamine (750 μl, 5.39 mmol), water (0.5 ml) and LiCl (478.0 mg, 11.28 mmol) were added. The reaction mixture was stirred over the weekend. Water was added and the resulting solution was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 100 % MeCN in 0.1 M NH₄OAc buffer was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was acidified to pH 3 with KHSO₄ (2M) and extracted from DCM. The organic phase was passed through a phase separator and the solvent was removed under reduced pressure. The residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. H-NMR (400 MHz, DMSO-d₆): -0.18 (s, 3H), -0.04 (s, 3H), 0.78 (s, 9H), 2.79-2.87 (m, 1H), 2.90-2.99 (m, 1H) 3.11 (t, 2H), 3.78 (d,

2H), 4.26 (d, 1H), 4.49 (t, 2H), 4.52 (s, 2H), 4.81 (t, 1H), 5.07 (d, 1H), 6.68 (d, 1H), 6.97-7.07 (m, 3H), 7.12-7.20 (m, 3H), 7.22-7.28 (m, 2H), 7.38 (d, 2H), 8.33 (bt, 1H). M/z: 679.36 (M-1).

5

***N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine**

10

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (20.4 mg, 0.030 mmol) and *N*-methylmorpholine (10 μ l, 0.090 mmol) in DCM (2 ml, dry) was added TBTU (11.6 mg, 0.036 mmol). The reaction mixture was stirred at 30°C for 1.5 hours. 3-methyl-D-valine (5.8 mg, 0.044 mmol) was added and the reaction mixture was stirred overnight. Water (1 ml) was added to the reaction mixture. The solvent was removed under reduced pressure and the residue was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 100 % ACN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and most of the MeCN was removed under reduced pressure. The residue was lyophilised to give the title compound as a white solid (8.5 mg, 36 %). M/z: 793.49 (M-1).

N-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine

5

To a stirred solution of {4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic
10 acid (23.0 mg, 0.037 mmol) and *N*-methylmorpholine (12 μ l, 0.111 mmol) in DMF (1 ml, dry) was added TBTU (16.6 mg, 0.052 mmol). The reaction mixture was stirred for 45 minutes at 30°C. Glycyl-D-valine hydrochloride (10.2 mg, 0.052 mmol) was added and the reaction mixture was stirred for 3.5 hours. The solution was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 10 to 95 % MeCN in 0.1M NH₄OAc
15 buffer was used as eluent. The pure fractions were collected and most of the MeCN was removed under reduced pressure. After lyophilisation, the title compound was obtained. M/z: 779.47 (M-1).

20 *N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-4-cyano-D-phenylalanine

25

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (20.8 mg, 0.031 mmol) and *N*-methylmorpholine (10 μ l, 0.092 mmol) in DMF (1 ml, dry) at 30 °C was added TBTU (13.8 mg, 0.043 mmol). The reaction
30 mixture was stirred at 30°C 1 hour. 4-cyano-D-phenylalanine hydrochloride (9.6 mg, 0.042 mmol) was added and the reaction mixture was stirred overnight. Water (1 ml) was added to the reaction mixture. The solution was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 100 % MeCN in a 0.1M NH₄OAc buffer was used as

eluent. Most of the MeCN was removed under reduced. The residue was lyophilised to give the title compound. M/z: 851 (M-1).

5 ***N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-*N*⁶,*N*⁶-dimethyl-L-lysine**

10

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (21 mg, 0.031 mmol) and *N*-methylmorpholine (10 μ l, 0.093 mmol) in DMF (1 ml, dry) was added TBTU (14 mg, 0.044 mmol). The reaction mixture was
15 stirred at 30°C for 45 minutes. *N*⁶,*N*⁶-dimethyl-L-lysine hydrochloride (10.0 mg, 0.047 mmol) was added and the reaction mixture was stirred for 2 hours. Water (1 ml) was added to the reaction mixture. The solution was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 10 to 100 % MeCN in 0.1 M NH₄OAc buffer was used as
20 eluent. Most of the MeCN was removed under reduced pressure and the residue was diluted with water. After lyophilisation, the title compound was obtained. M/z: 836 (M-1).

25 ***N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline**

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-[(2*R* or *S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline (20.8 mg, 0.031 mmol) in DMF (1 ml, dry) was added *N*-methylmorpholine (10 μ l, 0.088 mmol). The reaction mixture was stirred at
30 30°C for five minutes. TBTU (14.2 mg, 0.044 mmol) was added and the reaction mixture was

stirred for 1 hour. 3-methyl-D-isovaline (6.0 mg, 0.046 mmol) was added and the reaction mixture was stirred at 30°C for 2 hours. Water (1 ml) was added to the reaction mixture. The solution was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 10 to 100 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were
5 collected and most of the MeCN was removed under reduced pressure. The residue was lyophilised to give the title compound. M/z: 793 (M-1).

***N*-({4-[(2*R*,3*R*)-3-{{(2*R* or *S*)-2-{{*tert*-butyl(dimethyl)silyl}oxy}-2-(2,3-dihydro-1-
10 benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycylglycine**

To a stirred suspension of *N*-({4-[(2*R*,3*R*)-3-{{(2*R* or *S*)-2-{{*tert*-butyl(dimethyl)silyl}oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-
15 yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline (51.6 mg, 0.082 mmol) and methyl glycinate hydrochloride (54.2 mg, 0.43 mmol) in DCM were added *N*-methylemorpholine (119 µl, 1.07 mmol) and TBTU (139 mg, 0.43 mmol). The reaction mixture was stirred overnight. Water (0.5 ml) was added and the solvent was removed under reduced pressure. The residue was dissolved in MeCN (3 ml). Triethylamine (500 µl, 3.59 mmol), water (20 µl, 1.11 mmol) and
20 LiCl (330 mg, 7.78 mmol) were added and the reaction mixture was stirred overnight. Additional triethylamine (50 µl, 0.36 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was diluted with water and MeCN and the solution was purified with preparative HPLC on a C8 column. A gradient from 20 to 92 % MeCN in 0.1 M NH₄OAc was used as eluent. The MeCN was removed under reduced pressure. The fractions
25 containing the desired product were partitioned between water and DCM. The water phase was acidified to pH ca 3 with KHSO₄ (2M). The phases were separated and the organic phase was concentrated. The residue was diluted with MeCN and water and lyophilised to give the title compound. H-NMR (400 MHz, DMSO-*d*₆): -0.18 (s, 3H), -0.05 (s, 3H), 0.77 (s, 9H), 2.80-2.96 (dm, 2H), 3.11 (t, 2H), 3.68 (b, 2H), 3.78 (d, 2H), 4.26 (d, 1H), 4.46-4.51 (m, 2H),
30 4.52 (s, 2H), 4.79-4.83 (m, 1H), 5.06 (d, 1H), 6.67 (d, 1H), 6.97-7.05 (m, 3H), 7.12-7.19 (m, 3H), 7.21-7.27 (m, 2H), 7.37 (d, 2H), 8.09 (b, 1H), 8.31 (t, 1H). M/z: 736.39 (M-1).

1-(2,3-Dihydro-benzofuran-6-yl)-ethanone

5

A solution of bromo(2,3-dihydro-1-benzofuran-6-yl)magnesium (prepared from 6-bromo-2,3-dihydro-benzofuran (2.50 g, 12,56 mmol) and Mg (0.336 g, 13.8 mmol)) in THF (10 mL) was dropwise added to a solution of acetic anhydride (2.40 mL, 25.4 mmol) in Et₂O (10 mL) held
10 at -78°C. The reaction mixture was stirred at -78°C for 1h before the temperature was allowed to reach -10°C over a period of 1h. The reaction mixture was quenched by the addition of NH₄Cl (aq, saturated, 20 mL) and the resulting mixture was extracted twice with Et₂O (2x10 mL). The organic extracts were pooled, washed with NaOH (aq, 5%, 10 mL) and brine (10 mL), dried over MgSO₄ and concentrated under reduced pressure. The residue was
15 purified by preparative HPLC using a gradient of 20-50% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

¹H-NMR (CDCl₃, 400 MHz): δ 2.5 (s, 3H), 3.2 (t, 2H), 4.6 (t, 2H), 7.5-7.7 (m, 3H).

20

2-Bromo-1-(2,3-dihydro-benzofuran-6-yl)-ethanone

25 Br₂ (0.36 ml, 7.01 mmol) was added dropwise to a stirring solution of 1-(2,3-dihydro-benzofuran-6-yl)-ethanone (1.13 g, 6.97 mmol) in MeOH (20 mL) held at 0°C. The reaction mixture was slowly allowed to reach room temperature. After 3 h, the reaction was quenched by the addition of NaHCO₃ (aq, saturated)(until pH=8). Most of the methanol was removed under reduced pressure and the residue was extracted twice with EtOAc (2x20 mL). The
30 organic extracts were pooled, washed with brine (10 mL), dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by preparative HPLC using a gradient of 40-70% MeCN in a 0.1M ammonium acetate buffer as eluent. The fractions containing the desired product were pooled and most of the MeCN was removed under

reduced pressure. The residue was extracted with EtOAc (2x20 mL) and the combined organic layers was washed with brine, dried over MgSO₄ and concentrated. The obtained was finely washed MeOH to give the title compound.

5 ¹H-NMR (CDCl₃, 400 MHz): δ 3.25 (t, 2H), 4.39 (s, 2H), 4.61 (t, 2H), 7.24-7.36 (m, 2H), 7.45-7.52 (m, 1H).

10 **{4-[(2R,3R)-3-[2-(2,3-Dihydro-benzofuran-6-yl)-2-oxo-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid tert-butyl ester**

Triphenyl phosphine (50 mg, 0.191 mmol) was added to a solution of {4-[(2R,3R)-1-(4-
15 fluoro-phenyl)-3-(3-nitro-pyridin-2-yl)disulfanyl]-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid tert-butyl ester (100 mg, 0.179 mmol) in acetone/water (3 mL/0.5 mL) at room temperature. The mixture was stirred for 15 min. The solvent was removed under reduced pressure and the residue was dissolved in DCM (3 mL). Et₃N (75 µL, 0.534 mmol) and 2-bromo-1-(2,3-
dihydro-benzofuran-6-yl)-ethanone (91 mg, 0.377 mmol) were added and the solution was
20 stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC using a gradient of 40-80% MeCN in a 0.1M ammonium acetate buffer as eluent. The pure fractions were pooled and most of the MeCN was removed under reduced pressure. The residue was extracted with EtOAc and the organic layer was washed with brine, dried over MgSO₄ and concentrated. The title compound was
25 obtained.

¹H-NMR (CDCl₃, 400 MHz): δ 1.4 (s, 9H), 3.2 (t, 2H), 4.0 (d, 1H), 4.1 (s, 2H), 4.4 (s, 2H), 4.6 (t, 2H), 4.8 (d, 1H), 6.7-6.9 (m, 4H), 7.1-7.3 (m, 6H), 7.3-7.4 (m, 1H).

30

{4-[(2R,3R)-3-[2-(2,3-Dihydro-benzofuran-6-yl)-2-oxo-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid.

{4-[(2R,3R)-3-[2-(2,3-Dihydro-benzofuran-6-yl)-2-oxo-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid tert-butyl ester (77 mg, 0.137 mmol) was dissolved in formic acid (3 mL) and the solution was stirred for 1h at room temperature. The solvent
5 was removed under reduced pressure and the residue was dissolved in DCM. The solution was washed with water and then concentrated under reduced pressure. The residue was freeze-dried from MeCN/water to give the title compound.

¹H-NMR (DMSO, 500 MHz): δ 3.23 (t, 2H), 4.24-4.36 (m, 3H), 4.57 (t, 2H), 4.65 (s, 2H),
10 5.15 (d, 1H), 6.86-6.93 (m, 2H), 7.11-7.27 (m, 5H), 7.30-7.37 (m, 3H), 7.42-7.47 (m, 1H).

It will be appreciated by those skilled in the art that the examples may be modified within the
5 realms of the invention, why the invention is not limited to particular embodiments.


Absorption

- 10 Absorption of the compounds of formula (I) was tested in a Caco-2 cells model
(Gastroenterology 1989, 96, 736):

Compound (I)	Caco value (10^{-6} cm/sec)
<u>Example 1</u>	0.05

Claims

1. A compound of formula (I):



5

(I)

wherein:

- 10 X= -CH₂-, -CH₂CH₂-, or -CH₂CH₂CH₂-;

Y= -CH₂- or O;

Y₁= -CH₂- or O;

Wherein at least one of Y and Y₁ is -CH₂-;

R¹= H, C₁₋₆ alkyl, C₃₋₆cycloalkyl or aryl;


- 15 R¹ is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl or aryl; wherein said C₁₋₆alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C₁₋₆alkoxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁-C₆ alkylcarbonylamino C₁₋₆alkylS(O)_a wherein a is 0-2, C₃₋₆cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;
- 20 R² and R³ are independently hydrogen, a branched or unbranched C₁₋₆alkyl, C₃₋₆cycloalkyl or aryl; wherein said C₁₋₆alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, cyano, carbamoyl, carboxy, C₁₋₆alkoxy, aryl C₁₋₆alkoxy, (C₁-C₄ alkyl)₃Si, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a, C₃₋₆cycloalkyl, aryl or aryl C₁₋₆alkylS(O)_a, wherein a is 0-2; and wherein any aryl group may be optionally substituted by one
- 25 or two substituents selected from halo, hydroxy, cyano, C₁₋₆alkyl or C₁₋₆alkoxy;
- R⁴ is hydrogen, C₁₋₆ alkyl, or arylC₁₋₆ alkyl;
- wherein R³ and R² may form a ring with 3-7 carbon atoms and wherein R⁴ and R² may form a ring with 2-6 carbon atoms;

R^5 is selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl and

5 N,N -(C_{1-6} alkyl) $_2$ sulphamoyl; and wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

2. A compound of formula (I2):



wherein:

$X = -CH_2-$, $-CH_2CH_2-$, or $-CH_2CH_2CH_2-$;

15 $Y = -CH_2-$ or O ;

$Y_1 = -CH_2-$ or O ;

Wherein at least one of Y and Y_1 is $-CH_2-$;

$R^1 = H$, C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl;

20 R^1 is hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl; wherein said C_{1-6} alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C_{1-6} alkoxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkylcarbonylamino C_{1-6} alkylS(O) $_a$ wherein a is 0-2, C_{3-6} cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;

25 R^2 and R^3 are independently hydrogen, a branched or unbranched C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl; wherein said C_{1-6} alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, cyano, carbamoyl, carboxy, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, $(C_{1-4}$ alkyl) $_3$ Si, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkylS(O) $_a$, C_{3-6} cycloalkyl, aryl or aryl C_{1-6}

alkylS(O)_a, wherein a is 0-2; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, cyano, C₁₋₆alkyl or C₁₋₆alkoxy;

R⁴ is hydrogen, C₁₋₆alkyl, or arylC₁₋₆alkyl;

wherein **R**³ and **R**² may form a ring with 3-7 carbon atoms and wherein **R**⁴ and **R**² may form a

5 ring with 2-6 carbon atoms;

R⁵ is selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C₁₋₆alkyl,

C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino,

C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a

wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl and

10 *N,N*-(C₁₋₆alkyl)₂sulphamoyl; and wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

3. A compound according to claim 1 or 2, wherein X=-CH₂-.

15 4. A compound according to claim 1 or 2, wherein X=-CH₂CH₂-.

5. A compound according to claim 1 or 2, wherein X=-CH₂CH₂CH₂-.

6. A compound according to any of the preceding claims, wherein,

20 **R**¹ is hydrogen;

R² and **R**³ are hydrogen or a branched or unbranched C₁₋₆alkyl; wherein said C₁₋₆alkyl is substituted by C₃₋₆cycloalkyl, aryl or amino;

R⁴ is hydrogen.

25 7. A compound according to any of the preceding claims wherein,

R¹ is hydrogen;

R² and **R**³ are hydrogen or a branched or unbranched C₁₋₆alkyl; wherein said C₁₋₆alkyl is substituted by C₃₋₆cycloalkyl;

R⁴ is hydrogen.

30

8. A compound according to claim 7, wherein,

R² is hydrogen and **R**³ is *tert*-butyl.

9. A compound according to claim 7, wherein,

R^2 is hydrogen and R^3 is methyl; wherein said methyl is substituted by cyclohexyl.

10. A compound according to any of the preceding claims, wherein,

5 R^5 is selected from chlorine or fluorine.

11. One or more compound chosen from:

N-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-lysine;

10 *N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-b,b-dimethyl-D-phenylalanine; and
N-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-Dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine ammoniate;

15 *N*-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine;
N-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine;


N-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-4-cyano-D-phenylalanine;

20 *N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl- N^6,N^6 -dimethyl-L-lysine;
N-({4-[(2*R*,3*R*)-3-{[(2*R* or *S*)-2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline;

25 *N*-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycylglycine.

12. A compound of the (XVI):

- 94 -



Wherein:

5

X= -CH₂-, -CH₂CH₂-, or -CH₂CH₂CH₂-;

Y= -CH₂- or O;

Y₁= -CH₂- or O;

Wherein at least one of Y and Y₁ is -CH₂-;

10

R¹ is hydrogen, C₁₋₆ alkyl, C₃₋₆cycloalkyl or aryl;

R⁵ is selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a

15

wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl and *N,N*-(C₁₋₆alkyl)₂sulphamoyl; and wherein n is 0, 1, 2 or 3;

R⁷ is an hydroxy group or a C₁₋₄ alkoxy group.

20

13. A method of treating or preventing hyperlipidemic conditions comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.

25

14. A method of treating or preventing atherosclerosis comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.

15. A method for treating or preventing Alzheimers' disease comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.

5 16. A method for treating or preventing cholesterol associated tumors comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.


17. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 12 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.

18. A combination of a compound according to formula (I) or (I2) with a PPAR alpha and/or gamma agonist.

15 19. A combination of a compound according to formula (I) or (I2) with an HMG Co-A reductase inhibitor.


20. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprising any of the steps of:

Process 1) reacting a compound of formula (II):



(II)

25 with a compound of formula (III):




- 96 -

(III)


wherein L is a displaceable group;

Process 2) reacting an acid of formula (IV):




(IV)

or an activated derivative thereof; with an amine of formula (V):




(V)

Process 3): reacting an acid of formula (VI):




(VI)

or an activated derivative thereof, with an amine of formula (VII):




(VII)

Process 4): reducing a compound of formula (VIII):




(VIII)

Process 5): reacting a compound of formula (IX):



(IX)

with a compound of formula (X):




(X)

wherein L is a displaceable group;


Process 6): reacting a compound of formula (XI):

- 98 -




(XI)

wherein L is a displaceable group; with a compound of formula (XII):



(XII)

Process 7): De-esterifying a compound of formula (XIII)



(XIII)

wherein the group C(O)OR is an ester group.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/000765

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004005247 A1 (ASTRAZENECA AB ET AL), 15 January 2004 (15.01.2004), see especially compounds 25, 26 and 30 --	1-20
A	WO 9616037 A1 (SCHERING CORPORATION), 30 May 1996 (30.05.1996) --	1-20
A	US 5744467 A (BRIAN A. MCKITTRICK ET AL), 28 April 1998 (28.04.1998) --	1-20

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 Sept 2006

Date of mailing of the international search report

04-10-2006

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Renzo C. Verboom/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/000765

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-16
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 13-16 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/000765

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2006/000765

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BRIAN A. MCKITTRICK et al, "Synthesis of C3 Heteroatom-Substituted Azetidinones That Display Potent Cholesterol Absorption Inhibitory Activity", J. Med. Chem. 1998, vol. 41, pages 752-759</p> <p>-- -----</p>	1-20

International patent classification (IPC)

C07D 205/08 (2006.01)
A61K 31/397 (2006.01)
A61P 25/28 (2006.01)
A61P 3/06 (2006.01)
A61P 9/10 (2006.01)
C07D 405/12 (2006.01)

Download your patent documents at www.prv.se

The cited patent documents can be downloaded at www.prv.se by following the links:

- In English/Searches and advisory services/Cited documents (service in English) or
- e-tjänster/anförda dokument (service in Swedish).

Use the application number as username.

The password is **ZDWGIHWVKL**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

INTERNATIONAL SEARCH REPORT
Information on patent family members

04/03/2006

International application No.
PCT/SE2006/000765

WO	2004005247	A1	15/01/2004	AU	2003242850	A	00/00/0000
				BR	0312280	A	12/04/2005
				CA	2491789	A	15/01/2004
				CN	1665783	A	07/09/2005
				EP	1521742	A	13/04/2005
				GB	0215579	D	00/00/0000
				IS	7648	A	13/01/2005
				JP	2006501184	T	12/01/2006
				MX	PA04012936	A	16/05/2005
				NO	20050016	A	01/03/2005
				PL	374725	A	31/10/2005
				US	20050239766	A	27/10/2005
				ZA	200410340	A	20/10/2005

WO	9616037	A1	30/05/1996	AT	213726	T	15/03/2002
				AU	698750	B	05/11/1998
				AU	4140196	A	17/06/1996
				BR	9509669	A	28/10/1997
				CA	2205202	A,C	30/05/1996
				CN	1083833	B,C	01/05/2002
				CN	1174548	A	25/02/1998
				CZ	289033	B	17/10/2001
				CZ	9701486	A	12/11/1997
				DE	69525643	D,T	26/09/2002
				DK	792264	T	22/04/2002
				EP	0792264	A,B	03/09/1997
				SE	0792264	T3	
				ES	2169162	T	01/07/2002
				FI	116220	B	14/10/2005
				FI	972099	A	16/05/1997
				HK	1002558	A	00/00/0000
				HU	77088	A	02/03/1998
				JP	2908031	B	21/06/1999
				JP	9512833	T	22/12/1997
				KR	235806	B	01/02/2000
				NO	308468	B	18/09/2000
				NO	972272	A	16/05/1997
				NZ	296720	A	29/03/1999
				PL	184310	B	30/09/2002
				PL	320092	A	15/09/1997
				PT	792264	T	31/07/2002
				RU	2159243	C	20/11/2000
				SK	61697	A	10/12/1997
				SK	283860	B	02/03/2004
				US	5624920	A	29/04/1997
				US	5633246	A	27/05/1997
				US	5744467	A	28/04/1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

04/03/2006

International application No.

PCT/SE2006/000765

US	5744467	A	28/04/1998	AT	213726	T	15/03/2002
				AU	698750	B	05/11/1998
				AU	4140196	A	17/06/1996
				BR	9509669	A	28/10/1997
				CA	2205202	A,C	30/05/1996
				CN	1083833	B,C	01/05/2002
				CN	1174548	A	25/02/1998
				CZ	289033	B	17/10/2001
				CZ	9701486	A	12/11/1997
				DE	69525643	D,T	26/09/2002
				DK	792264	T	22/04/2002
				EP	0792264	A,B	03/09/1997
				SE	0792264	T3	
				ES	2169162	T	01/07/2002
				FI	116220	B	14/10/2005
				FI	972099	A	16/05/1997
				HK	1002558	A	00/00/0000
				HU	77088	A	02/03/1998
				JP	2908031	B	21/06/1999
				JP	9512833	T	22/12/1997
				KR	235806	B	01/02/2000
				NO	308468	B	18/09/2000
				NO	972272	A	16/05/1997
				NZ	296720	A	29/03/1999
				PL	184310	B	30/09/2002
				PL	320092	A	15/09/1997
				PT	792264	T	31/07/2002
				RU	2159243	C	20/11/2000
				SK	61697	A	10/12/1997
				SK	283860	B	02/03/2004
				US	5633246	A	27/05/1997
				WO	9616037	A	30/05/1996
				US	5624920	A	29/04/1997
